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ABSTRACT 
 
THE ADDITION OF MELATONIN TO 17β-ESTRADIOL AND PROGESTERONE 
MODULATED MARKERS RELEVANT TO MAMMARY TUMOR DEVELOPMENT 
AND MODULATED STEROID RECEPTORS RELEVANT TO UTERINE 
PROTECTION IN A MOUSE MODEL OF BREAST CANCER 
 
By 
Corry Dominic Bondi 
August 2013 
 
Dissertation supervised by Paula Witt-Enderby, Ph.D. 
The use of hormone replacement therapy (HRT) is important to relieve 
menopausal symptoms.  However, HRT use declined after an increased risk of breast 
cancer was reported by the Women’s Health Initiative.  With the ultimate goal of 
developing a novel replacement therapy to relieve menopausal symptoms without 
increasing the risk of breast cancer, we postulated that a novel replacement therapy 
containing 17β-estradiol (E2) and half the recommended dose of progesterone (P4) along 
with nocturnal melatonin supplementation (EPMRT) would be protective against 
mammary tumor development.  Previously, in a mouse model of HER2+ breast cancer, 
our laboratory demonstrated that EPMRT was protective against mammary cancer by 
increasing mammary tumor latency, decreasing tumor incidence and weight, and 
decreasing gross lung metastases while not increasing uterine weight.  A pre-tumor study 
 v 
was conducted to gain insight into these protective effects.  Randomized, non-
ovariectomized, 60-day old female MMTV/unactivated Neu mice were provided 
therapies comprised of E2 and P4, with or without nocturnal melatonin supplementation, 
given continually for 30 days.  To investigate actions on mammary tissues, whole mount, 
microarray, and real-time RT-PCR analyses were performed.  To assess impact on the 
uterus, uterine wet weight, luminal epithelial height, estrogen receptor (ERα) and 
progesterone receptor (PR) expression, as well as Ki67 expression were performed.  
Tertiary side-branching, the initial step in the process of mammary ductal differentiation, 
was significantly increased by Melatonin and EPMRT as compared to Control.  Also, 
EPMRT displayed significantly decreased expression of the cancer-related genes 
encoding amphiregulin and indoleamine 2, 3-dioxygenase.  In the uterus, there were no 
differences detected in wet weight, luminal epithelial height, and proliferation.  Also, 
there was no effect on serum E2 or P4 levels; however, EPMRT increased the time in 
estrus.  Moreover, the increase in expression of aromatase mRNA by low dose P4 was 
abolished by increasing doses of P4 and by addition of melatonin.  Overall, these data 
provide important insight into the protective actions of EPMRT on Neu-induced 
mammary cancer.  These findings provide a rationale for future investigations with the 
ultimate goal of having women use this novel therapy to relieve menopausal symptoms 
while providing protective actions on the breast and the uterus.     
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BACKGROUND 
 As a woman progresses through life, changes in her hormone levels, specifically 
estrogen, progesterone (P4), and melatonin, produce symptoms such as hot flashes, 
vaginal atrophy, sleep disturbances, anxiety, and depression [1, 2].  These symptoms can 
be debilitating and leads her to seek relief.  A therapy prescribed to women for relief of 
these symptoms, especially hot flashes, is hormone replacement therapy (HRT).  
Clinically, HRT is used to restore the hormone balance lost during menopause, a state 
characterized by estrogen deficiency resulting from the loss of ovarian function.  In 
addition to alleviating menopausal symptoms (i.e., hot flashes and vaginal atrophy), HRT 
is used to reduce the risk of heart disease, osteoporosis, and to improve mood, thereby, 
improving quality of life within this population [1]. 
 As more and more women were taking HRT for relief of menopausal symptoms, a 
randomized, placebo-controlled study was established called the Women’s Health 
Initiative (WHI) to investigate the health risks and benefits of HRT in postmenopausal 
women ages 50 to 79.  This study used a common HRT, PREMPRO
®
 (formally Wyeth 
Ayerst, Collegeville, PA), that contains conjugated equine estrogens (CEE) combined 
with medroxyprogesterone acetate (MPA).  The results revealed that women taking 
PREMPRO
®
 had an increased risk in developing breast cancer [3-5].  Following the 
initial reports from the WHI, the use of HRT declined dramatically in the United States 
[1] impacting negatively a menopausal woman’s quality of life. 
 The increase risk of breast cancer with the combined therapy, that is HRT 
therapies containing both an estrogen and a progestogen, is controversial.  The WHI 
revealed that PREMPRO
®
 increased the risk of breast cancer [6]; however, the E3N 
 2 
prospective cohort study of postmenopausal, metropolitan French women revealed that 
17β-estradiol (E2) plus P4 did not increase the risk of breast cancer.  Moreover, the type 
of progestogen included along with E2 may be an important contributor to the increased 
risk of breast cancer.  E2 plus dydrogesterone was not associated with an increase in risk 
of breast cancer; but, E2 plus other progestogens such as nomegestrol acetate and 
promegestone were associated with an increase in risk [7].  Also, in another study, 
combination therapies with norethindrone acetate increased the risk breast cancer as 
compared to MPA when used for more than 5 years [8].  In a postmenopausal primate 
model, E2 combined with micronized P4 did not increase Ki67 expression, an indicator 
of DNA synthesis, in lobular and ductal breast epithelium as compared to placebo; 
however, E2 combined with MPA increased Ki67 expression indicating an increase in 
DNA synthesis and cell proliferation [9].  Women taking PREMARIN
®
 (CEE) 
demonstrated a decreased risk of breast cancer suggesting a possible association of 
progestogens in increasing this risk.  However, the results of the WHI were in contrast to 
the E3n study that revealed a 1.3 fold increase in breast cancer risk associated with the 
use of E2 alone [7, 10, 11].  These studies suggest that the progestogen component of the 
HRT may be an important contributor to the associated increased the risk of breast 
cancer.   
In addition to the type of hormones used in the HRT, the doses of these hormones, 
time of initiation of therapy, and length of exposure were found to be important as well.  
The authors of the Endocrine Society Scientific Statement urge that “continued research 
on the lowest doses … is necessary [1].”  Thus, doses of HRT should be at the lowest 
effective dose that provides symptom relief.  For example, 0.5mg of micronized oral E2 
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provided relief from hot flashes [12] so this low dose should be considered versus higher 
doses for menopausal symptom relief.  The length of exposure and initiation of therapies 
were critical to the development of breast cancer.  For example, P4 usage for five years or 
less, as a component of an HRT, may not increase breast cancer risk [13, 14].  However, 
women taking estrogen alone or E2 plus progestogen therapies closer to menopause had 
an increased risk of breast cancer compared to women with a longer gap time [14].  
Moreover, women taking PREMPRO
®
 who were closer to menopause (less than five 
years) were at a somewhat greater risk compared to women taking PREMPRO
®
 who 
were more than five years after menopause [3].  Therefore, the timing of HRT use as it 
relates to menopause, the duration of usage, and the dose of HRT all seem to contribute 
to the risk of breast cancer, but the data are unclear.   
With the ultimate goal of relieving menopausal symptoms without increasing the 
risk of breast cancer and offering uterine protection, we postulated that a novel, HRT 
containing E2 and half the recommended dose of P4 along with nocturnal melatonin 
supplementation (EPMRT) would not increase and could potentially decrease mammary 
tumor development and be uterine protective in a mouse model of HER2+ breast cancer.  
Half the clinically recommended dose of P4 was used to assess if the reduced dose would 
decrease mammary cancer development in our mouse model even though this P4 dose 
may not be sufficient to reduce E2-mediated uterine stimulation.  However, because 
melatonin has both anti-estrogenic and anti-cancer actions in the body, it is hypothesized 
that nocturnal melatonin supplementation will prevent mammary tumor development and 
protect the uterus from excessive estrogen exposure.       
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In another study assessing the efficacy of EPMRT on mammary cancer in this 
same model, our laboratory demonstrated that EPMRT was protective against mammary 
cancer by increasing tumor latency, decreasing tumor incidence, decreasing tumor 
weight, and by decreasing gross lung metastases while remaining uterine protective [15].  
Together, these results indicate that EPMRT provided a protective action in the 
mammary gland, as well as inhibited effects on the uterus even though half the 
recommended dose of P4 was used.  The possible early events (i.e., pre-tumor) 
underlying the protective effects of EPMRT are unknown.  Therefore, the results 
described herein may provide insight into the protective actions of EPMRT on mammary 
tumorigenesis and against excessive uterine proliferation in order to advance the future 
use of EPMRT in women experiencing menopausal symptoms.     
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HYPOTHESIS and SPECIFIC AIMS 
Hypothesis 
The addition of melatonin to 17β-estradiol and half the clinically recommended 
dose of progesterone will modulate markers relevant to mammary tumor development 
and uterine protection in female MMTV/unactivated Neu mice. 
Specific Aim 1 
To determine estrogen, progesterone, and/or melatonin effects on mammary 
ductal development and gene expression which are relevant to mammary tumor 
development in female MMTV/unactivated Neu mice.   
Specific Aim 2 
To determine estrogen, progesterone, and/or melatonin effects on uterine weight, 
cellular hypertrophy and proliferation, and ERα and PRA expression which are relevant 
to uterine protection in female MMTV/unactivated Neu mice. 
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INTRODUCTION 
Cancer 
 Hippocrates used the word “Cancer” to describe diseases in which tissues grow 
and spread throughout the body.  Cancer develops from disruptions in the homeostatic 
balance between the rate of cell division, and the rate of cell differentiation and loss 
possibly due to factors such as radiation or chemical exposures, heredity, and viruses.  
Therefore, the homeostatic balance is shifted toward greater cell division due to a loss of 
growth control that results in tumor formation.  Malignant tumors (i.e., cancer) are life-
threatening because tumor cells can invade surrounding tissues and metastasize to other 
parts of the body.  Depending on the origin of the tumor cell type, cancers are categorized 
as carcinomas (originating from epithelial tissues), sarcomas (originating in supporting 
tissues of mesodermal origin), and lymphomas (originating from lymphatic and blood 
cells) [16]. 
 Cellular proto-oncogenes (e.g., unactivated Neu in this study) are normal cellular 
genes that can be converted into oncogenes by various mechanisms including, but not 
limited to, mutations (e.g. point or frame deletions), amplification (i.e., an increase in 
gene copy number), insertional mutagenesis (e.g., an integrated retrovirus), DNA 
rearrangement, or chromosomal translocation.  Therefore, the conversion of a proto-
oncogene to an oncogene produces proteins that are structurally abnormal or over-
expressed [16].  Oncogenes encode proteins involved in growth control, such as receptor 
tyrosine kinases (e.g., mouse ERBB2 receptor and human HER2/ERBB2 receptor).  
Through the expression of these proteins, oncogenes disrupt normal growth control by 
induction of cell proliferative, anti-apoptotic, and/or pro-survival pathways.        
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Breast cancer 
According to the National Cancer Institute, breast cancer is defined as “cancer 
that forms in tissues of the breast, usually the ducts (tubes that carry milk to the nipple) 
and lobules (glands that make milk) [17]” with the former being the most prevalent.  
Ductal carcinoma in situ (DCIS) is the most common of the non-invasive cancers with 
60,000 newly diagnosed cases each year at a rate of 1 out of every 5 cases.  DCIS has not 
metastasized and originates from the epithelial tissue lining the milk ducts.  However, 
invasive ductal carcinoma (IDC) is the most prevalent form of invasive breast cancer 
with 180,000 new diagnoses each year and is more common in women over 55 [18] .   
Breast cancer statistics 
 Breast cancer is the most commonly diagnosed cancer and ranks second in overall 
cancer-related deaths of women in the United States [19].  During 2012, an estimated 
226,870 women will be diagnosed with breast cancer (i.e., 26% of new cases each year) 
and 39,510 are expected to die from this malignancy.  The median age at diagnosis is 61 
years, and as of January 1, 2009, over 2.7 million women living in the U.S. have a history 
of breast cancer [19, 20].  With breast cancer having such a negative impact on national 
public health, scientific research into ways to reduce the development of this cancer is 
paramount.     
 The age-adjusted incidence for all races was 124.3 per 100,000 women per year 
with incidence ranked by race from highest to lowest: White > Black > Asian / Pacific 
Islander > American Indian / Alaska Native > Hispanic.  The median age of death was 68 
with the highest percentage of mortality between 55 to 84 years and the age-adjusted 
death rate of 23.0 per 100,000 women per year.  For the years 2002 to 2008, the 5-year 
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relative survival was 89.0%; however, the survival was greater for white women than 
black women (i.e., a difference of 12.6%) [20]. 
 Early detection and diagnosis is important for an overall 5-year relative survival.  
The stage distribution and the 5-year relative survival by stage at diagnosis are as 
follows: 60% are diagnosed as Localized with a 98.4% survival; 33% are diagnosed as 
Regional (i.e., spread to regional lymph nodes) with a 83.9% survival; 5% are diagnosed 
as Distant (i.e., metastasized) with 23.8% survival; and 2% are diagnosed as Unknown 
with a 50.7% survival.  The overall lifetime risk, as calculated from rates between 2007 
to 2009, is 12.48%.  Based on these data, 1 in 8 women born today will be diagnosed 
with breast cancer during their lifetime with the highest risk (i.e., 3.45% or 1 in 29) 
occurring from age 60 to 69 [20].        
Risk factors              
There are multiple risk factors that contribute to the development of breast cancer 
such as age, family history, lack of or late parity, age of first menarche, late menopause, 
and exogenous hormone exposures from HRT [21, 22].  Moreover, other exposures may 
include high fat diet, pharmaceuticals, food additives, and environmental pollutants [23-
26].  Interestingly, a study investigating breast cancer development in identical twins 
suggests that 27% of breast cancer has a genetic component while 73% may result from 
unknown environmental exposures [27].   
HER2+ breast cancer  
 In women, amplification of the ERBB2 gene, which encodes the HER2 receptor 
that belongs to the epidermal growth factor receptor family, as well as increased HER2 
receptor expression, is demonstrated in up to two-thirds of in situ ductal and one-third of 
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invasive ductal breast cancers [28-31].  ERBB2 amplification occurs in about 20% to 30% 
of primary breast cancers and subsequent HER2 receptor over-expression impacts 
negatively on prognosis [32].  Clinically, various methods are used to detect ERBB2 
amplification or HER2 receptor expression.  Fluorescence in-situ hybridization (FISH) 
assesses ERBB2 amplification and is considered the more precise, accurate, and 
reproducible test.  The Dako “Herceptest,” a semi-quantitative immunohistochemical test, 
assesses receptor over-expression based on intensity and completeness of membrane 
staining [33, 34].   
Breast cancer treatments 
 The most common form of treatment for DCIS is a lumpectomy followed by 
radiation therapy; however, mastectomy or hormonal therapy may also be utilized for 
treatment.  Treatments for IDC are broader based and include surgery (e.g., mastectomy), 
radiation, chemotherapy, anti-hormonal, and biopharmaceutical agents.  Chemotherapies 
include various classes of antineoplastic agents such as alkylating (e.g., 
cyclophosphamide) and intercalating agents (e.g., doxorubicin and epirubicin) that inhibit 
DNA replication, antimetabolite and antifolate agents (e.g., capecitabine, 5-fluorouracil, 
and methotrexate) that inhibit RNA and DNA syntheses, as well as agents (e.g., docetaxel 
and paclitaxel) that inhibit microtubule disassembly leading to cell-cycle arrest [35].  
Anti-hormonal therapies include selective estrogen receptor modulators (e.g., tamoxifen), 
aromatase inhibitors (e.g., anastrozole), estrogen receptor down-regulators (e.g., 
fulvestrant) and estrogen reducers (e.g., goserelin).  Biopharmaceutical agents include 
targeting the HER2 receptor by use of monoclonal antibodies (e.g., trastuzumab), or by 
use of HER2 activated kinase inhibitors (e.g., lapatinib).  The other therapies are directed 
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towards the HER2/HER3 heterodimers (e.g., pertuzumab), or by inhibiting angiogenesis 
with VEGF inhibition (e.g., bevacizumab) [36].   
Hormone replacement therapy  
 Hormone replacement therapy (HRT) is given clinically to women to replenish 
the hormone reduction that occurs during menopause.  The rationale for using HRT is 
primarily to reduce menopausal symptoms of hot flashes and vaginal atrophy as well as 
to reduce the risk heart disease, colon cancer, and osteoporosis [1].  HRT consists of two 
main types: an estrogen alone replacement therapy or an estrogen plus progestogen 
replacement therapy.  Even though the current consensus is that estrogen alone therapy 
reduces breast cancer risk, one problem with this therapy is the increased risk of 
endometrial hyperplasia and type I endometrial cancer [1, 6]; therefore, the addition of a 
progestogen counteracts the hyperplastic actions of estrogen resulting in no increased risk 
of endometrial cancer [1, 6, 37].   
In the United States, the most widely prescribed progestogen, until recently, was 
the progestin, MPA [38] primarily as a combined therapy with CEE (i.e., PREMPRO
®
).  
Outside of the United States, other combinations of HRT are used; for example, in 
France, the estrogen component is predominately E2 combined with one of the various 
progestogens, such as P4 and dydrogesterone [7].     
Women’s Health Initiative and other studies 
 HRT has been used in clinical practice for many years and is known to be 
beneficial for cardiovascular health [39], prevention of osteoporosis [40] as well as for 
relief of menopausal symptoms [1].  Therefore, a definitive assessment of HRT was 
proposed under direct impetus of the late Dr. Bernadine Healy, then Director of the U.S. 
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National Institutes of Health [6].  In response, the WHI was established to conduct two 
large, full-scale, randomized, placebo-controlled trials in postmenopausal women aged 59 
to 79 years with one study using PREMARIN
®
 (i.e., estrogen-only replacement therapy) 
in postmenopausal women with a previous hysterectomy and the other study using 
PREMPRO
®
 (i.e., estrogen-progestin combination therapy) in postmenopausal women 
with an intact uterus [6].   
The randomized, placebo-controlled study with PREMPRO
®
 was stopped after a 
mean of 5.6 years because health risks exceeded benefits.  Moreover, this study revealed 
an increased risk of invasive breast cancer in addition to having a higher risks of heart 
disease, stroke, and blood clots [4, 5, 41].  However, the increased risk of breast cancer 
declined after discontinuing HRT [41, 42].  Follow-up results revealed that PREMPRO
®
 
increased mortality, invasive breast cancer incidence, and lymph node-positive cancers.  
In the Million Women Study, an increase in mortality in women diagnosed with breast 
cancer while using estrogen plus progestin therapy was observed [43].  However, it was 
also observed that a 40% reduction in mortality occurred in trials in which the mean age 
was less than 60 years and within ten years of menopause onset [1].  Furthermore, 
women taking PREMPRO
®
 who were closer to menopause (less than five years) were at 
somewhat greater risk for breast cancer compared to women taking PREMPRO
®
 who 
were five years or more since menopause [3].  A greater risk of developing breast cancer 
was also observed in the French E3N prospective cohort study as to the use of HRT 
closer to menopause [14].   
 Results from randomized clinical trials suggest that estrogen alone therapy 
reduces breast cancer incidence while estrogen plus progestin increases breast cancer 
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incidence and death [6].  However, within the last decade, it was believed that estrogen 
alone therapy as well as estrogen plus progestin therapy increased the incidence of breast 
cancer; however, estrogen alone therapy required longer exposure than the combination 
[6].  In the WHI, estrogen-only therapy in postmenopausal women who had a 
hysterectomy resulted in a reduced risk of breast cancer [10], while many observational 
studies contradicted this finding [7, 43-47].  However, in the other arm of the WHI, 
women taking the combination therapy, PREMPRO
®
, had an increased risk of breast 
cancer [4].  In response to WHI findings, the use of PREMPRO
® 
and PREMARIN
® 
in the 
United States declined [48].  Even though HRT increased the risk of breast cancer [4, 5] 
and is classified as a known carcinogen based on the results of the WHI as well as in 
observational studies [49], HRT is beneficial for improving the quality of life of women 
suffering from hot flashes and vaginal atrophy.  For example, a risk and benefit analysis 
revealed that there was a greater benefit achieved by use of this therapy compared to the 
relative risk.  In this analysis, it was observed that per 1000 women per five years of HRT 
use, 800-900 women would receive benefit from an improvement in menopausal 
symptoms (i.e., hot flashes and vaginal atrophy, respectively) while  approximately 7.5 
women would be at risk for breast cancer [1].   
Melatonin synthesis  
Melatonin (i.e., N-acetyl-5-methoxytryptamine) is known to have important roles 
in entraining one’s sleep/wake cycle, as well as having important roles in reproductive 
processes [50].  Melatonin is synthesized and secreted by the pineal gland in response to 
darkness with peak plasma levels occurring approximately at 02:00 hours (2 am) [51, 52].  
In response to darkness, the retina, via the retino-hypothalamic tract, sends signals to the 
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suprachiasmatic nucleus (SCN), the master biological clock.  Activation of the neurons 
within the SCN results in the activation of the superior cervical ganglion that then sends 
signals to the pineal gland to initiate the synthesis of melatonin by inducing the rate-
limiting enzyme, serotonin-N-acetyltransferase [53, 54].   
The synthesis of melatonin is a two-step process with serotonin as a precursor.  
During the first step, serotonin, via N-acetylation by the enzyme serotonin-N-
acetyltransferase, is converted to N-acetylserotonin.  During the second step, N-
acetylserotonin, via O-methylation by the enzyme hydroxyindole-O-methyltransferase, is 
converted to melatonin [54].  By contrast, melatonin synthesis is reduced in response to 
light via the depolarization of retinal ganglion cells that innervate the SCN thereby 
reducing sympathetic signaling [53], and light exposure at night inhibits the increase in 
plasma levels of melatonin through a suppression of the pineal gland [55].  
Melatonin synthesis and secretion follows a diurnal rhythm whereby levels are 
highest during the hours of darkness and lowest during the hours of light.  The release of 
melatonin begins at dusk and persists for eight to sixteen hours depending on the season.  
Summer months have the shortest duration of melatonin exposure whereas the winter 
months have the longest duration [56].  Therefore, melatonin receptors are exposed to 
melatonin for long periods of time during the hours of darkness and during the winter 
months that may lead to reduced cellular proliferation and enhanced cellular 
differentiation.  For example, chronic exposure to melatonin, in vitro, modulates 
signaling cascades (i.e., cAMP-dependent or MAPK pathways) leading to reduced 
cellular proliferation and enhanced cellular differentiation [57-60].   
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Melatonin production is inhibited in middle and older aged adults to as much as 
one-eighth as that of young adults [61].  Also, as a woman ages, her levels of melatonin 
decline especially the nocturnal peak of melatonin.  This decline in nocturnal melatonin 
levels may contribute the sleep disturbances and vasomotor symptoms (i.e., hot flashes) 
associated with menopause [2].  
Melatonin pharmacokinetics 
The following summary of information was obtained from Micromedex
®
 2.0 
which compiled the information contained herein from a variety of sources.  Melatonin is 
rapidly absorbed with peak serum levels occurring within one hour.  Because of extensive 
hepatic first pass metabolism, the oral bioavailability is poor in humans (mean 33%), but 
is higher in rats (53%), dogs, and monkeys (both 100%).  Because melatonin is highly 
lipophilic, it crosses the blood-brain barrier, as well as readily distributes to most tissues 
including the ovaries.  After hepatic metabolism, the primary metabolite of melatonin is 
6-hydroxymelatonin, with up to 85% of the given dose excreted in the urine as 6-
hydroxymelatonin sulfate.  The elimination half-life following an oral dose ranges from 
30 to 50 minutes [62].          
Melatonin receptors 
 Melatonin produces its effects independent of receptors via free radical 
scavenging or through up-regulation of anti-oxidant enzyme and/or in a receptor 
dependent manner through G-protein coupled receptors.  There are two melatonin 
receptors, MT1 and MT2, that are seven transmembrane receptors belonging to the G-
protein (i.e., guanine nucleotide-binding protein) coupled receptor family.  The activation 
of melatonin receptors by melatonin results in an inhibition of adenylyl cyclase via 
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pertussis toxin sensitive G-proteins [63]; this results in an inhibition of protein kinase A 
and the transcription factor, cAMP response element-binding (CREB), thereby reducing 
gene transcription [56, 64].  Additionally, an activated melatonin receptor may signal via 
Gq proteins to stimulate phospholipase C (PLC) leading to an increase in 
phosphoinositide hydrolysis resulting in an increase of intracellular calcium [65].  Also, 
melatonin, via the melatonin receptors, can activate the MAP kinase signal transduction 
pathway [58, 59, 66] through β-arrestin scaffolds [57, 60] producing effects on cell 
proliferation and differentiation. 
Melatonin receptor expression  
 Melatonin receptors have been detected throughout the body including the brain, 
retina, cardiovasculature, kidney, gut, bone, reproductive organs, and mammary gland 
[67, 68].  With respect to each melatonin receptor subtype, some tissue specificity has 
been observed.  For example, MT2 receptors are expressed centrally in the SCN and 
cortex and peripherally in ovarian granulosa cells, kidney, adipocytes, retina, and blood 
vessels.  MT1 receptors are expressed centrally in the cerebellum, SCN, and pituitary 
gland as well as peripherally in ovarian granulosa cells, retina, kidney, pancreas, and 
blood vessels [68].  Furthermore, endogenous expression of melatonin receptors has been 
detected in various cell lines.  For example, human breast cancer (MCF-7) cells, human 
prostate cancer (LNCaP) cells, mouse neuroblastoma (N1E-115) cells, as well as human 
embryonic kidney (HEK-293) cells, express MT1 receptors while human 
choriocarcinoma (JAR) cells, various melanocytes and melanoma cells [68], and human 
adult mesenchymal stem hAMSC cells [58] express MT2 receptors.     
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In vitro oncostatic effects of melatonin  
Melatonin produces oncostatic effects in vitro and in vivo through multiple 
mechanisms including its free radical scavenging and antioxidant properties [69, 70], by 
inhibiting aromatase expression and activity [71], by inhibiting ER-mediated gene 
expression [72], and through its effects on MAPK signaling pathways.  These actions of 
melatonin lead to a reduction in cellular proliferation [73-77] and an induction in cellular 
differentiation [59, 66, 78]. 
Most of the studies to date reveal that the oncostatic effects of melatonin are 
elicited mostly through anti-estrogen actions.  Specifically, melatonin inhibits gonadal 
estrogen synthesis, down-regulates estrogen receptor (ER) expression, inhibits the 
binding of the E2-ERα complex to the estrogen response element (ERE), and inhibits 
aromatase expression and activity [71].   
The anti-estrogenic actions result in decreases in cellular proliferation.  For 
example, a physiological concentration of melatonin (1 nM) attenuates proliferation of 
MCF-7 breast cancer cells by inhibiting the binding of the E2-ERα complex to the ERE 
[79] resulting in a down-regulation of the cyclin D1 gene [72].  The mechanisms 
underlying melatonin-mediated inhibition of E2-ERα complex binding to ERE may be 
through receptor-independent and -dependent pathways.  For example, melatonin inhibits 
the binding of the complex to EREs through an inhibition of calmodulin-sensitive 
adenylyl cyclases [50].  However, using dominant negative and positive G-proteins, it 
was found that the suppression of E2-induced ERα transcriptional activity by melatonin 
occurs through Gαi2 and not Gαq proteins [80].  Also, in serum-starved MCF-7 cells 
transiently expressing MT1 receptors, melatonin attenuates E2-induced expression of 
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BRCA-1, P53, P21(WAF) and c-MYC, and this attenuation by melatonin is enhanced with 
increasing receptor expression [81].    
In addition to blocking the E2-ERα complex to EREs, melatonin (1nM) attenuates 
aromatase expression and activity in MCF-7 cells [71].  This dose also inhibits steroid 
sulfatase and 17β-hydroxysteroid dehydrogenase type 1 but stimulates sulfotransferase 
[82] thereby reducing the conversion of sulfated metabolites to more potent non-sulfated 
forms of estrogens such as E2 and estrone (E1).     
Besides MCF-7 cells, melatonin (100 pM to 100 nM) inhibits cellular 
proliferation in Chinese hamster ovary cells [73], human neuroblastoma SK-N-SH cells 
[74], rat hepatoma AH-130 cells [75], rat pheochromocytoma PC-12 cells [76], human 
mesenchymal stem hAMSC cells [58], mouse embryonic fibroblast NIH-3T3 cells [83], 
and mouse melanoma S-91 cells.  Interestingly, in mouse melanoma S-91 cells, the 
potency of melatonin to inhibit cell proliferation increases 1000 fold (i.e., EC50 = 100 nM 
to EC50 = 100 pM) following stable expression of MT1 receptors [77].  These studies 
demonstrate the importance of melatonin activation of melatonin receptors in the 
inhibition of cellular proliferation. 
In many of the aforementioned studies, and concomitant to the anti-proliferative 
effects of melatonin, increases in cellular differentiation were demonstrated.  For 
example, in Chinese hamster ovary (CHO) or B(E)2C cells, stably expressing melatonin 
receptors, or in cells endogenously expressing these receptors (e.g., N1E-115 and 
hAMSC), melatonin induces cellular differentiation as reflected by the induction of 
outgrowths or the differentiation of hAMSCs into osteoblasts [58, 59, 66, 78].  Also, 
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melatonin (1 nM or 1 mM) induces the differentiation of 3T3-L1 mouse embryonic 
fibroblasts into an adipocyte-like phenotype [84].      
Preclinical oncostatic effects of melatonin    
Melatonin inhibits cellular proliferation and induces cellular differentiation in 
cancer cell in vitro models.  Melatonin has also been demonstrated to protect against 
cancer in vivo using approaches that suppress endogenous melatonin production.  Initial 
studies demonstrate that pinealectomy as well as constant light exposure enhanced 
chemically-induced mammary carcinogenesis, and exogenous administration of 
melatonin under the conditions attenuated these effects [85, 86].  Light exposure during 
the dark phase of the light:dark cycle promotes the uptake of linoleic acid and its 
metabolism to 13-hydroxyoctadecadienoic acid, a mitogenic signaling molecule, in rat 
hepatoma (7288CTC) cells and human breast xenographs thereby promoting tumor 
proliferation.  Nocturnal supplementation with melatonin inhibits these processes through 
melatonin receptor-mediated mechanisms [87].  Furthermore, constant light (0.21 Lux) 
exposure during the dark phase of a 24-hour light:dark cycle increases the growth of 
dimethylbenzanthracene (DMBA)-induced mammary adenocarcinomas in female 
Sprague-Dawley rats; this increase in tumor growth rate was accompanied by lower 
survival.  Examination into the potential mechanisms underlying the increase in tumor 
growth by constant light exposure at night suggests that low nocturnal melatonin levels 
and high E2 levels may be involved.  In these mice exposed to light at night, levels of 
serum E2 were higher, vaginal cornification typical of persistent estrus was observed, and 
a lack of day-night rhythm of melatonin release occurred [88].   
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These data suggest that mammary tumor growth may be inhibited, in part, due to 
the anti-estrogenic effects of melatonin.  For example, S-23478-1, a melatonin receptor 
agonist, suppressed N-nitroso-N-methyl-urea-induced mammary tumors in rats via 
attenuation of ERα expression and signaling [89].  In rats with E2-induced pituitary 
prolactin secreting tumors, melatonin administration (0.25 mg and 0.50 mg/day/rat for 97 
days) inhibits proliferation as well as induces apoptosis [90].   
Clinical oncostatic effects of melatonin  
In 1978, Cohen, Lippman, and Chabner postulated a relationship between pineal 
function and estrogen responsive breast cancer [91].  For example, women shift workers 
exposed to light during the night reveal a higher incidence of breast cancer compared to 
non-shift workers [92-95].  By contrast, the degree of visual impairment has been 
correlates inversely with breast cancer incidence [96]; for example, blind women have a 
low incidence of breast cancer [97, 98].  Whether or not this is due to the oncostatic 
actions of melatonin alone, through anti-estrogenic actions of melatonin, or both still 
needs to be determined.  However, due to its multiple anti-estrogenic actions, especially 
the ability to act as a selective estrogen enzyme modulator (SEEM), the use of melatonin 
as an adjuvant to existing therapies for preventing and treating breast cancer is warranted 
and is currently being tested clinically [99-101]. 
Action of melatonin on progesterone and 17β-estradiol 
 An inverse relationship between melatonin and E2 exists; that is, when melatonin 
levels are high, E2 levels are low and when melatonin levels are low, E2 levels are high 
[102].  Besides E2, melatonin also has a relationship with P4 except that levels of 
melatonin are positively correlated with P4 [102].  The mechanisms underlying the 
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positive relationship between melatonin and P4 could be through the actions of melatonin 
on granulosa cells.  For example, melatonin, at concentrations of 200 pg/mL and 100-400 
pg/mL, directly stimulates the secretion of P4 from human and bovine granulosa cells in 
serum supplemented media, respectively [103].  Moreover, although melatonin exposure 
has no effect on basal P4 production in human granulosa-luteal cells, melatonin enhances 
human chorionic gonadotropin (hCG)-stimulated P4 production possibly through 
melatonin receptors coupled to the MAPK pathway [104].  In bovine granulosa cells, 
melatonin stimulates P4 production and inhibits E2 biosynthesis in a time-dependent 
manner [105].  Also, female Wistar rats, sacrificed two months after pinealectomy, have 
reduced serum levels of P4 and increased serum levels of E2 as well as decreases in 
progesterone receptor (PR) expression in the ovaries[106].  Finally, in women, melatonin 
administration (3 mg/day at 22:00 h) during the luteal phase of the menstrual cycle 
increases serum P4 concentrations [107].  
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METHODS 
Drugs  
 Progesterone [57-83-0] (#57830), 17β-estradiol [50-28-2] (#2758) and melatonin 
[73-31-4] (#5250) were purchased from Sigma-Aldrich (St. Louis, MO).  
Rationale for use of model 
The use of transgenic mouse models has revealed that transgenes participate and 
activate oncogenic pathways involved in neoplastic progression.  The key features are 
summarized by these five rules as directly quoted from Cardiff: 1) “Mammary 
development is related to the type and amount of transgene expressed;” 2) “dysplasias 
and tumors develop from secondary mutations;” 3) “the transgenes determine tumor 
phenotype;” 4) “transgenes may activate dominant oncogenic pathways;” and 5) “the 
oncogenic pathway determines prognosis [108].”   
 The mouse mammary tumor virus (MMTV) belongs to the Retroviridae family.  
A retrovirus (i.e., RNA virus) encodes the enzyme, reverse transcriptase, which catalyzes 
the synthesis of DNA from an RNA template resulting in the formation of a provirus.  
The provirus is integrated into the host’s genome and replicated.  In mice, the MMTV 
replicates in the alveolar epithelial cells of the mammary gland [109].  In 
MMTV/unactivated Neu transgenic mice, rat Neu transcripts, in addition to the mammary 
gland, are also detected in the salivary glands, spleen, thymus, and lungs [110].   
 MMTV mouse models are relevant for the study of breast cancer because of the 
latency, histology, and invasiveness of the mammary tumors.   Sacco et al. 2003 
presented an eloquent description of the relevance of one of the MMTV models (i.e., the 
MMTV/activated Neu) to human breast cancer.  Taking the liberty of quoting directly; 
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“Breast tumors in MMTV-Neu mice occur spontaneously, over-express the Neu 
oncogene, escape the immune system, grow in situ and adapt to the microenvironment, 
recruit vessels, invade the tissues, penetrate the vasculature, and give rise to distant 
metastases [111].”   
The FVB/N strain of mice are descendants of an outbred colony of Swiss mice 
N:GP (i.e., NIH general purpose mouse) established in 1935.  The FVB/N are favorable 
for transgenic generation because of large litter size (e.g., mean 9.5), large and prominent 
pronuclei of the zygote that facilitates microinjection of DNA, as well as a high 
percentage (i.e., 74%) of embryo survival after injection resulting in an increased birth 
number compared with other mouse strains [112].  FVB/N mice do not form spontaneous 
tumors and at 24 months of age have no detectable mammary carcinomas [112, 113].  
However, transgenic FVB/N female mice, expressing the rat Neu proto-oncogene under 
the transcriptional control of the MMTV promoter, demonstrate decreased mammary 
tumor latencies compared to transgenic C56BL/6 females expressing the same transgene 
under the control of the MMTV promoter (i.e., between 7 to 12 months compared to > 18 
months) [114].            
 The Neu (i.e., Erbb2) proto-oncogene encodes a 185 kDa receptor tyrosine kinase 
(i.e., ERBB2 receptor) belonging to the epidermal growth factor receptor family.  
Amplification and over-expression of the human homologue of the Neu proto-oncogene 
(i.e. ERBB2 gene) is demonstrated in up to two-thirds of in situ ductal and one-third of 
invasive ductal breast cancers [28-31] and is correlated with poor prognosis [32].  An 
earlier transgenic mouse model was developed that utilized an oncogenic form of the rat 
Neu (i.e., activated) gene under the transcriptional control of the MMTV promoter that 
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results in the expression of activated ERBB2 receptors in the mammary epithelia.  
Activation of these ERBB2 receptors results from a valine to glutamic acid substitution in 
the transmembrane domain.  Even though this mutation has been observed in chemically-
induced neuroblastomas, analyses of breast cancer biopsies have not detected this 
mutation in the transmembrane domain of ERBB2, thus suggesting an involvement of 
receptor over-expression rather than the activated receptor [32, 115, 116].  Therefore, to 
investigate the role of receptor over-expression in mammary carcinogenesis, a transgenic 
mouse model [FVB/N-Tg(MMTVneu)202Mul/J] was developed containing the rat Neu 
proto-oncogene (i.e., unactivated) under the transcriptional control of the MMTV 
promoter [110].  The use of the rat Neu transgene allows for the identification and 
characterization of effects as compared to the endogenous mouse gene. 
This transgenic model mimics the stochastic nature of breast cancer and develops 
focal mammary adenocarcinomas (i.e., carcinoma of glandular tissue), surrounded by 
hyperplastic mammary epithelia, by four months of age with an average latency of about 
seven months (mean onset of 205 days).  Metastasis to the lungs is common with 72% of 
tumor-bearing mice living to an age of eight months or older develop metastatic disease.  
Histological examination reveals multiple foci of metastatic mammary adenocarcinomas 
in the pulmonary vessels [110].  Also, tumor formation is not pregnancy dependent [110].  
The role of estrogen in tumor development has been suggested because ovariectomy, as 
well as tamoxifen administration, prevents mammary tumor development [117, 118].  No 
amplification of either the rat Neu transgene or endogenous mouse Neu (i.e., Erbb2) gene 
has been detected in these tumors, unlike in human breast tumors.  However, over-
expression of the transgene and the ERBB2 receptors exhibiting intrinsic tyrosine kinase 
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activity has been detected suggesting an increase in transcription rate or RNA stability 
[110].   
The elevated tyrosine kinase activity may be mediated by receptor over-
expression as well as by somatic mutations that promote catalytic activation through 
homo- and heterodimerization.  Specifically, PCR analysis reveals that 65% of tumors, 
but not adjacent mammary epithelia, express ERBB2 receptors containing deletions of 7 
to 12 amino acids (i.e., from in-frame deletions of 21 to 36 base pairs) located in the 
extracellular domain.  Moreover, there is no difference between the transcript levels of 
the altered and unactivated transgenes [119].  The expression of the altered Neu cDNAs 
in Rat-1 fibroblasts results in tyrosine-phosphorylated ERBB2 receptors suggesting 
oncogenic activation of ERBB2 receptors [119].  Therefore, the deletion of these amino 
acids in the extracellular domain may contribute to the formation of disulfide-linked 
receptor dimers through a favorable particular spatial arrangement between the cysteines 
[120].  The activation of ERBB2 may involve signaling through c-SRC because 
mammary tumor extracts contain higher levels of c-SRC kinase activity without an 
increase in the level of c-SRC, and the activation of c-SRC results from direct interaction 
of the SH2 domain with the activated ERBB2 receptor [121].    
In postmenopausal women with breast cancer, tumors that are ER negative confer 
a poorer prognosis than tumors that are ER positive [122].  Tumors in the 
MMTV/unactivated Neu mice are characterized by low ER expression (i.e., 10 fmol/mg 
protein) with PR expression even lower, and tumors are classified as two subtypes, ER+, 
PR- and ER-, PR- [123].  Normal and abnormal hyperplastic ducts of pubertal mice 
demonstrate about 75% of ERBB2-positive epithelial cells are ERα negative [124].  
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Tumor-derived cell lines exhibit expression of mouse ERBB3 receptors and ERβ but not 
ERα [125].  Tumors also exhibit increased expression of activated ERBB2, ERBB3, 
SRC, GAB2, SHC, Rb, ERK, and AKT as well as express higher levels of EGFR, 
ERBB4, Cyclin D1, p15, p27, and GLUT1 [126]. 
Description of model  
All animal care was reviewed and approved by The Duquesne University 
Institutional Animal Care and Use Committee (IACUC) according to institutional 
guidelines following the National Institutes of Health guidelines for humane use.  All 
female mice were obtained from in-house breeding of wild-type FVB/N females (Jackson 
Laboratory, Bar Harbor, ME) with dizygous males (FVB/N-Tg(MMTVneu)202Mul/J) 
carrying the unactivated (i.e., proto-oncogene), rat Neu transgene under transcriptional 
control of the MMTV promoter (Jackson Laboratory) [110].   
Experimental design 
The animal colony was maintained under a 12:12 light-dark cycle and allowed 
access to isoflavone-free diet and water, ad libitum.  The isoflavone-free diet (i.e., the 
Control diet) was the Harlan-Tekland AIN-93G diet modified with corn oil providing 
3713 kcal/kg with a nutrient content of 20% casein protein, 16% fat, and 64% 
carbohydrate (Harlan Laboratories Inc., USA) [127].  The focus of the pre-tumor study 
was to gain insight into the protective actions of the treatments on mammary 
carcinogenesis; therefore, this investigation used the same treatment conditions as in the 
long-term tumor study, Control, Melatonin, EPRT, EPMRT [15].  At weaning, female 
mice were randomly assigned to these four groups as shown in Table 1.   
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 Isoflavone-free Diet 
(Continuous) 
Isoflavone-free Diet containing 
0.5 mg E2 + 50 mg P4 
(Continuous) 
Water containing Vehicle 
(Night only) 
Control EPRT  
Water containing Melatonin 
(Night only) 
Melatonin  EPMRT 
 
Table 1.  Treatment groups  
 
    
 
 
Diagram 1.  Experimental timeline 
All mice were maintained on isoflavone-free diet and water, ad libitum, until 
postnatal day 60 (See Diagram 1).  At postnatal day 60 (i.e., two months of age), the mice 
began exposure to the treatment conditions.  Depending on the experimental group, 
nocturnal melatonin supplementation (final concentration of 15 mg/L) was delivered in 
the drinking water during the hours of darkness.  This supplementation was prepared 
daily by dissolving melatonin in 95% ethanol and then diluting this stock solution with 
water to a final concentration of 15 mg/L.  Mice in the melatonin group were given 
melatonin in the drinking water between the hours of 18:00 to 06:00 (i.e., 6 p.m. to 6 
a.m.) each day for 30 days.  Each mouse in the Melatonin and EPMRT groups would be 
consuming approximately 52.5 µg of melatonin per period of darkness based on the 
measured mean nightly consumption of 3.5 mL of water.  The melatonin dose is 
approximately equivalent to 5 mg of melatonin consumed by an adult woman per night.  
PND 21 
(Weaning) 
Isoflavone-free diet & 
water 
PND 60 
(Treatment Begins) 
PND 90+ 
(Confirm in Estrus) 
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Mice not consuming the nocturnal melatonin supplementation were provided water 
containing a final ethanol concentration of 0.03% (i.e., vehicle water). 
Depending on the experimental group, mice were provided a combination of 17β-
estradiol (E2) and progesterone (P4) in the isoflavone-free diet.  The hormones were 
blended into the diet by the supplier.  The isoflavone-free diet containing the hormones 
was provided, ad libitum, to the EPRT and EPMRT groups beginning at postnatal day 60 
and continuing until postnatal day 90, or after, until the mouse was in estrus, as 
confirmed by visualization of the vaginal smear.  The dose of E2 (0.5 mg) or P4 (50 mg) 
was added to 1800 kcal of diet, the average daily caloric intake of a woman [128], to 
account for the metabolic differences between mice and humans.  Therefore, the final 
daily hormonal doses consumed by the mice eating 18 kcal or approximately 4 g of diet 
would be 5 µg of E2 and 500 µg of P4.  Following completion of the experimental 
timeline, the mice were euthanized by carbon dioxide inhalation, and tissues were 
collected and frozen immediately or processed as described below.   
Tissue collection and processing  
Mammary gland collection:  The left upper and inguinal mammary glands were 
fixed with cold 4% paraformaldehyde for 24 hours before storage at room temperature in 
70% ethanol.  The right inguinal mammary glands were cut into four transverse sections, 
frozen immediately in liquid nitrogen, and stored at -80
o
C. 
Serum collection:  Whole blood was obtained via cardiac puncture and transferred 
to ice-cold Serum Gel S/1.1 tubes (#41.1387.005, Sarstedt Inc., Newton, NC).  Tubes 
were placed on ice, and blood was allowed to clot before centrifugation at 16,500 g for 
five minutes, and then stored at -20
o
C.   
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Ovary and uterus collection: Ovaries were frozen immediately in liquid nitrogen 
and stored at -80
o
C.  The whole uterus was weighed and then cut into transverse sections 
(i.e., cross-sections), fixed in cold 4% paraformaldehyde for 24 hours, and stored at room 
temperature in 70% ethanol.  Alternatively, after sectioning, some sections were frozen 
immediately with liquid nitrogen and stored at -80
o
C.   
Radioimmunoassay  
To assess the effect of the treatments on E2 and P4, the serum levels of E2 were 
assessed using the Double Antibody Estradiol kit (Diagnostic Products Corp., Los 
Angeles, CA) according to manufacturer’s protocol.  Briefly, a standard curve was 
generated with the provided standards.  To 200 µL of serum sample, 100 µL of “Estradiol 
Antiserum” was added, vortexed, and incubated at room temperature for two hours.  
After incubation, 100 µL of [
125
I] estradiol was added to all sample tubes, vortexed, and 
incubated at room temperature for one hour.  After incubation, 1.0 mL of cold 
Precipitating Solution was added to all sample tubes, vortexed, and incubated at room 
temperature for 10 minutes.  After incubation, all sample tubes were centrifuged at 3,000 
g for 15 minutes.  The supernatant was removed, and the precipitated pellet was retained 
for counting.   Tubes containing the precipitated pellet were counted for five minutes 
each with a Packard Cobra II Gamma Counter.  Serum levels of E2 were determined 
using the standard curve.          
Serum levels of P4 were assessed with the Coat-A-Count
®
 Progesterone kit 
(Diagnostic Products Corp, Los Angeles, CA) according to manufacturer’s protocol.  
Briefly, a standard curved was generated with the provided standards.  To 100 µL of 
serum sample, 1.0 mL of [
125
I] progesterone was added, vortexed, and incubated at room 
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temperature for three hours.  After incubation, the tubes were decanted thoroughly, and 
tubes were counted for five minutes each with a Packard Cobra II Gamma Counter.  
Serum levels of P4 were determined with the standard curve.      
Vaginal smear cytology 
 To assess whether or not the treatments regulated the estrous functioning of the 
female mice, vaginal smears were performed daily for 30 days in the morning by vaginal 
lavage.  The vaginal canals were washed gently three times with sterile 0.9% NaCl 
solution delivered by a dropper.  After the third wash, a drop of lavage fluid was placed 
onto a glass slide and allowed to air dry.  These slides were stained using the Diff Quick 
Stain Kit (Imeb, Inc, San Marcos, CA).  Briefly, the slides were immersed by dipping 15 
times into 100% methanol, 15 times into Solution B (i.e., eosin and xanthene dye), and 15 
times into Solution C (i.e., azure dye).  The slides were rinsed with deionized water and 
allowed to air dry.  Imaging was accomplished with a Nikon Eclipse E400 phase contrast 
microscope with an attached QImaging MicroPublisher 5.0 RTV camera (QImaging, 
Canada).  Electronic images were captured using QCapture software (QImaging, 
Canada).  The stage of the estrous cycle (i.e., proestrus, estrus, metestrus, or diestrus) for 
each day was determined by light microscopy at 400x after observation of three 
independent fields per smear by the investigator “blinded” to the treatment groups.  To 
determine the stage of the estrous cycle, the investigator utilized criteria reported 
previously [129, 130].  Figure 1 depicts representative photos of each stage of the estrous 
cycle.  Proestrus was identified by predominance of nucleated epithelial cells; estrus was 
identified by predominance of irregular, keratinized squamous epithelial cells with no 
visible nuclei; metestrus was identified by a mix of cell types with a predominance of 
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leukocytes along with the keratinized epithelial cells; diestrus was identified by the 
predominance of leukocytes with the absence of keratinized epithelial cells [129].  An 
overall mean +/- SEM for various estrous cycling parameters was calculated for each 
treatment group. 
    
 
Figure 1.  Representative images of each stage of the estrous cycle 
Mammary morphology 
To assess whether or not melatonin, HRT, or the combination therapy induced 
any morphological changes including effects on ductal elongation and mammary ductal 
differentiation, mammary whole mount analysis was performed on left inguinal 
mammary glands.  Carmine alum stain (1 g Carmine alum and 2.5 g Aluminum 
potassium sulfate, added to 500 mL deionized water and boiled for 20 minutes) was 
prepared.  After boiling, the volume was adjusted to 500 mL with deionized water, 
filtered, a crystal of thymol added, and then stored at 4
o
C.  The mammary glands were 
placed into cassettes and washed at room temperature for 15 minutes with 70% ethanol 
and then washed at room temperature for five minutes with deionized water.  Each 
mammary gland was then incubated at 4
o
C overnight carmine alum stain.  The next day, 
each mammary gland was washed at room temperature for 15 minutes each in a graded 
series of ethanol (i.e., 70%, 95%, and 100%).  Next, each mammary gland was incubated 
for at least 40 minutes with toluene to defat and clear the glands.  Each mammary gland 
Proestrus Estrus Metestrus Diestrus 
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was then stored at room temperature in methyl salicylate (Sigma Aldrich) until imaging 
analysis.  For imaging, each mammary gland was placed into a glass petri dish and 
immersed with methyl salicylate.  Imaging was accomplished with a Nikon SMZ 800 
dissecting microscope with an attached Olympus DP70 camera.  Electronic images were 
captured using DP control software (Olympus Optical Co. LTD. 2002), and these images 
were saved by DP Manager.  Measurements were calibrated with a metric ruler, and the 
parameters were quantified by the investigator “blinded” to the treatments groups using 
Image J software.  Figure 2 depicts how ductal elongation and the number of tertiary side 
branches were quantified.  Specifically, the elongation of the ducts into the mammary fat 
pad (depicted by black arrow labeled “A”) and the overall length of the mammary fat pad 
(depicted by black arrow labeled “B”) were determined by measurement from the center 
of the lymph node to the farthest terminal duct or the leading edge of the gland, 
respectively.  An overall mean +/- SEM was calculated for each treatment group.  
Tertiary branching was determined by quantifying the number of tertiary branches per 
mm
2 (depicted by black box labeled “C”) in three separate distal ductal containing areas 
of the gland.  The mean number of tertiary branches per mm
2
 was determined for each 
mammary gland per mouse in each treatment group.  An overall mean +/- SEM was 
calculated for each treatment group.     
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Figure 2.  Representative image of a mammary gland depicting how the duct and 
mammary gland lengths and number of tertiary branches were measured.  The large 
nodule is the mammary lymph node.  
Total binding assay  
To determine whether or not melatonin receptors are expressed in mammary 
tissue, total 2-[
125
I] iodomelatonin binding analysis was determined in inguinal mammary 
glands of Control mice.  Briefly, membranes were prepared from frozen cross-sections of 
inguinal mammary glands of Control mice through homogenization of the tissue in 1 mL 
of Tris buffer (50 mM Tris-HCl, pH 7.4) containing protease inhibitors.  Homogenates 
were then centrifuged at 20,000 g for 30 minutes.  Membranes were resuspended in 1 mL 
of ice-cold Tris buffer (pH 7.4) and then vortexed gently to resuspend the membranes.  
Aliquots of these membrane homogenates were either subjected to protein analysis using 
the Bradford method according to manufacturer’s protocol or total binding analysis using 
2-[
125
I] iodomelatonin radioligand (PerkinElmer, Waltham, MS).  Briefly, membrane 
2mm B C 
A 
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aliquots of 200 µL were added to tubes containing 1 nM 2-[
125
I] iodomelatonin in the 
absence (i.e., Total binding) or presence of 1 µM melatonin (i.e., Non-specific binding).  
Tubes were incubated at room temperature for one hour and then filtered using a Brandel 
harvester through Whatman GF/B Paper (FP-100) filter strips presoaked in 0.5% 
polyethylenimine (PEI) to reduce non-specific binding.  Radioactivity was counted for 
five minutes with a Packard Cobra II Gamma Counter.  Data were expressed as fmoles of 
2-[
125
I] iodomelatonin per mg of protein and then a mean was calculated.   
RNA isolation 
 To ascertain the effect of the various treatments on gene expression, microarray 
and real-time RT-PCR analysis was performed with RNA prepared from central sections 
of frozen right inguinal mammary gland.  RNA was isolated from tissues weighing 
between 30-90 mg using the Absolutely RNA
®
 Miniprep Kit (Stratagene, La Jolla, CA) 
according to the manufacturer’s protocol.  Briefly, the gland was placed into a 1.5 mL 
microfuge tube and homogenized in lysis buffer containing β-mercaptoethanol with a 
disposable RNase-free plastic douncer.  The homogenate was frozen at -20
o
C.  Once 
frozen, the homogenate was then thawed at room temperature.  To the Prefilter Spin Cup, 
700 µL of homogenate was added, centrifuged at 15,000 g for five minutes, and the 
filtrate was retained.  To the filtrate, an equal volume of 70% ethanol was added and 
vortexed thoroughly.  To the RNA Binding Spin Cup, 700 µL of mixture was added, 
centrifuged at 15,000 g for one minute, and the filtrate was discarded.  To the RNA 
Binding Spin Cup, the remaining 700 µL of mixture was added, centrifuged at 15,000 g 
for one minute, and the filtrate was discarded.  To the RNA Binding Spin Cup, 600 µL of 
1x Low-Salt Wash Buffer was added, centrifuged at 15,000 g for one minute, and filtrate 
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was discarded.  An additional centrifugation was performed for two minutes.  To the 
RNA Binding Spin cup, 55 µL of DNase solution was added directly to the filter matrix 
and incubated at 37
o
C for 15 minutes.  After incubation, 600 µL of 1x High Salt Buffer 
was added, centrifuged at 15,000 g for one minute, and filtrate was discarded.  Then, 600 
µL of 1x Low-Salt Wash Buffer was added, centrifuged at 15,000 g for one minute, and 
the filtrate was discarded.  Next, 300 µL of 1x Low-Salt Wash Buffer was added, 
centrifuged at 15,000 g for two minutes, and filtrate was discarded.  The RNA Binding 
Spin Cup was transferred to a 1.5 mL microfuge tube and 40 µL of pre-warmed (i.e., 
60
o
C) Elution Buffer was added gently onto the center of the filter matrix.  The 
microfuge tube was incubated at room temperature for two minutes and centrifuged at 
15,000 g for one minute.  The elution step was repeated to maximize RNA yield.  The 
RNA quantities and purities were determined by UV spectrophotometry (Beckman DU
®
 
530 Life Sciences UV/Vis spectrophotometer).  RNA dilutions were prepared with 
RNase-free water.  The RNA quantities were calculated using the equation: 
Concentration = A260nm x dilution factor x 0.4 µg/µL.  The RNA purities were determined 
by calculating the 260 nm / 280 nm ratio where ratios between 1.8 and 2.0 were 
considered as pure preparations.  The purified RNA was stored in -80
o
C until analysis.              
Microarray 
Microarray analysis was performed with the isolated RNA by the Biomedical 
Genomics Core of The Research Institute at Nationwide Children’s Hospital, Columbus, 
Ohio.  Arrays were scanned with the Affymetrix GeneChip Scanner 3000 7G and 
information extracted from image data by GeneChip Operating Software (GCOS) version 
1.4., and then analyzed in-house with the R-software environment for statistical 
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computing and graphics.  These scripts utilize several Bioconductor packages which 
provide tools for the analysis and comprehension of genomic data [131].  Genes were 
identified if the fold change was less than or equal -1.5 or greater than or equal to 1.5 of 
the Control samples. 
RT-PCR reactions 
Based on the findings from the microarray analysis, genes were further analyzed 
by real-time RT-PCR analysis to confirm the results.  Candidate genes were selected for 
further analysis if the genes were hormone-regulated, growth-promoting, related to cell 
differentiation, or involved in tumorigenesis.  Genes were also selected to serve as 
controls for the amount of mammary epithelial tissue (e.g., Krt18), lymph-node and 
lymphocyte contamination (e.g., Ms4a1) and the rat Neu (e.g., Erbb2) regulation.  Using 
the isolated RNA, 250 ng of total RNA was reversed transcribed into cDNA using the 
qScript™ cDNA Synthesis Kit (Quanta BioSciences, Inc., Gaithersburg, MD).  Briefly, a 
mixture containing 19 μL of total volume was prepared by adding qScript™ Nuclease 
Free Water, qScript™ Reaction Mix, and isolated RNA into a thin-walled PCR tube, 
vortexed, and centrifuged at low gravitational force.  To this tube, 1 µL of qScript™ 
Reverse Transcriptase was added, inverted gently to mix, and centrifuged at low 
gravitational force.  Another mixture containing 19μL of total volume was prepared by 
adding qScript™ Nuclease Free Water, qScript™ Reaction Mix, and isolated RNA, but 
without the addition of qScript™ Reverse Transcriptase enzyme.  An Eppendorf 
Mastercycler Epgradient (Eppendorf AG, Hamburg, Germany) was used to generate the 
cDNA.  The cDNA samples generated for each mouse were stored at -20
o
C.         
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Real-time RT-PCR 
 The cDNA samples from the RT-PCR reactions were used for real-time analysis.  
cDNA products were analyzed using primers designed for detection of:  Adra1a 
(adrenergic receptor, alpha 1a) F: 5’-TGG GCG CTT TCC TTG GTC ATC TC-3’ and R: 
5’-TAC GGT GGA TAC GGA GCG TCA-3’; Akr1c14 (aldo-keto reductase family 1 
member C14) F: 5’-GGA ACC ACT GTG CCC GAT AAG G-3’ and R: 5’-TGG CCT 
GGC CTA CTT CCT CTT CT-3’; Areg (amphiregulin) F: 5’-CTT TGT CTG TGC CAT 
CAT CC-3’ and R: 5’-TCC CTG AAG TAT CGT TTC CA-3’; Csn1s2a (casein alpha s2-
like) F: 5’-CAG AGC AGT GTG AAC CAG TG-3’ and  R: 5’-GGT ATC TGG GGA 
TGA AGA GC-3’; Duox1 (dual oxidase 1) F: 5’-ACC ATT TCC ATC ATG GGG TTC 
CA-3’ and R: 5’-GGG GGT TAG GCA GGT AGG GTT C-3’; Erbb2 (v-erb-b2 
erythroblastic leukemia viral oncogene homolog 2) F: 5’-TGG ATG TAC CTG TAT 
GAG ACG-3’and R: 5’-GGA TTC AAG CAG CAA GGA AAG-3’; Esr1 (estrogen 
receptor 1, alpha) F: 5’-TAT GCC TCT GGC TAC CAT TAT-3’ and R: 5’- CAT CAT 
GCC CAC TTC GTA AC-3’; Figf (c-fos induced growth factor or vascular endothelial 
growth factor D, VEGF-D) F: 5’-GGA GAT CTC ATT CAG CAC CCG GA-3’and R: 
5’-TGG GCC CTT GTC TCC TTT GGA A-3’; Greb1 (gene regulated by estrogen in 
breast cancer protein) F: 5’-CCT CCA CCA TGC AGC CCA TAT C-3’ and R: 5’-AGC 
GTA GGA AGA TCT GCT CCA GG-3’; Ido1 (indoleamine 2,3-dioxygenase 1) F: 5’-
GTT CTC ATT TCC TGG TGG GGA CT-3’ and R: 5’-AGC TAT GTC GTG CAG TGC 
CT-3’; Krt18 (keratin 18) F: 5’-TTG CGA ATT CTG TGG ACA AT-3’ and R: 5’-TTC 
CAC AGT CAA TCC AGA GC-3’; Lcn2 (lipocalin 2) F: 5’-CAA TGT CAC CTC CAT 
CCT GGT CA-3’ and R: 5’-CAG CCC TGG AGC TTG GAA CAA AT-3’; Ms4a1 
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(membrane spanning 4-domains, subfamily A, member 1 or B-lymphocyte antigen 
CD20) F: 5’-TGC CTT CTT CCA GAA ACT TG-3’ and R: 5’-TTG GTT GGG AAG 
ATA CTC CA-3’; Mtnr1a (melatonin receptor 1A) F: 5’-GCA ACA AGA AGC TCA 
GGA AC-3’ and R: 5’-ATG TCA GCA CCA AGG GAT AA-3’; Mtnr1b (melatonin 
receptor 1B) F: 5’-GTC TGG CTC CTC ACT CTG GT-3’ and R: 5’-AGG AAT AGA 
TGC GTG GAT CA-3’; Per2 (period homolog 2, Drosophila) F: 5’-CTG ACG CAC 
ACA AAG AAC TG-3’ and  R: 5’-TCA TTA GCC TTC ACC TGC TT-3’; Pgr 
(progesterone receptor) F: 5’-GGC AAA TCC CAC AGG AGT TTG-3’ and R: 5’-AGA 
CAT CAT TTC CGG AAA TTC-3’; Pgr(A) (progesterone receptor A) F: 5’-AG TGG 
TGG ATT TCA TCC ATG-3’ and R: 5’-CTT CCA GAG GGT AGG TG-3’; Ptprd 
(protein tyrosine phosphatase receptor type D) F: 5’-TTC GCC GTG TCC CAC CAA 
GA-3’ and R: 5’-GGC TTG GGT AAG GCT TTG ACA GT-3’; Slc24a3 (solute carrier 
family 24 member 3 sodium/potassium/calcium exchanger) F: 5’-CGC TGT CTG TGG 
TCG CAC TC-3’ and R: 5’-GAT CAC GGA CGC TTT GCG GT-3’; St3gal5 (ST3 beta-
galactoside alpha-2,3-sialytransferase 5) F: 5’-CTA GCA TGC ACA CAG AGG CGG T-
3’ and R: 5’-GTG AAC TCA CTT GGC ATT GCT CG-3’; Ppia (peptidylprolyl 
isomerase A or cyclophilin A) F: 5’-AGG TGA AAG AAG GCA TGA AC-3’ and R: 5’-
ACA GTC GGA AAT GGT GAT CT-3’.   
The primers were designed to span at least one intron / exon boundary, whenever 
possible, to ensure that the amplification was from cDNA and not genomic DNA.  All 
primers were purchased from Integrated DNA Technologies, Inc. (Coralville, IA).  The 
efficiencies of the primers were tested before use to insure the primers are appropriate.  
To a PCR microfuge tube, 5 μL of diluted primers and 12.5 μL of B-R SYBR® Green 
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SuperMix for iQ (Quanta BioSciences, Inc., Gaithersburg, MD) were added.  To a second 
PCR microfuge tube, 1 µL of the cDNA sample (from prior RT-PCR reaction) and 6 μL 
of UltraPure Distilled DNase- RNase-Free Water (Invitrogen Corp., Grand Island, NY) 
were added.  To a third PCR microfuge tube, 1 µL of the no reverse transcriptase 
containing mixture (from prior RT-PCR reaction) and 6 μl UltraPure Distilled DNase- 
RNase-Free Water were added.  Into each well of an ABgene
®
 plate (Thermo Fisher 
Scientific, UK), 18 μL of the primer mix and 7 μL of the template mix or the no reverse 
transcripase mix were added.  All samples were performed in duplicate.  In addition to 
the no reverse transcriptase wells, wells containing water only (i.e., no template) were 
analyzed to detect amplification of contaminants.  The plates were sealed and spun before 
placement into the Bio-Rad iCycler iQ™ real-time system set for SYBR green detection.   
The real-time conditions were designated for enzyme activation at 95
o
C for three 
minutes followed by 50 cycles of 15 seconds each at 95
o
C for denaturing and 45 seconds 
each at 60
o
C for annealing/extension.  To assess the quality of product, melt curves were 
generated to ensure a single product in each cDNA sample as well as comparison to the 
no reverse transcriptase samples.  Data was expressed as the change in threshold cycle 
value (ΔCt), whereby the lower the ΔCt value the higher the relative mRNA level 
contained in the sample.  The ΔCt value of each sample was calculated by subtracting the 
Ct of Ppia (i.e., cyclophilin A) from the Ct value of the candidate gene for each mouse in 
each treatment.  An overall mean ΔCt +/- SEM was calculated for each treatment group.  
Fold change of gene expression as compared to Control were determined for each 
treatment with the 2
-ΔΔCt 
method [132].   
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Immunohistochemistry  
To assess whether or not the treatments affected uterine weight, luminal epithelial 
height, and proliferation, fixed uteri from each of the groups were processed with a 
Shandon Pathcentre
®
 Tissue Processor/Embeddor and then manually embedded in 
paraffin using a Shandon Histocentre 2
®
 with a paraffin temperature of 64.5
o
C to avoid 
antigen degradation.  Cross-sections of 5 µm were generated using a Microm HM 325 
microtome.  The cross-sections were allowed to float on water warmed to 37
o
C before 
placement on ProbeOn slides (Fisher Scientific, Pittsburgh, PA).   
Each section was deparaffinized with three changes of mixed xylenes of five 
minutes each and then hydrated by a graded series of diluted ethanol concentrations 
(100% 2x, 90% 2x, 70% 2x, and 50% 1x) for 5 minutes each.  Each section was washed 
two times for five minutes each with tap water.  Antigen retrieval was performed using 
boiling citrate buffer (0.1 M Citric acid and 0.1 M sodium citrate dehydrate, pH 6.0) for 
15 minutes.  After boiling, each section remained in the citrate buffer and was allowed to 
cool on ice until buffer obtained room temperature.  Each section was washed four times 
for five minutes each with PBS (0.58 M sodium phosphate dibasic, 0.17 M sodium 
phosphate monobasic, and 0.68 M NaCl, pH 7.4).  Each section was then incubated in 
0.6% hydrogen peroxide (1:5 dilution of 3% hydrogen peroxide to 100% methanol) for 
eight minutes to quench endogenous peroxidase activity.  Each section was washed three 
times for five minutes each with 1x PBS.  A hydrophobic barrier was first created around 
the tissue sections using a PAP pen followed by incubation at room temperature for 15 
minutes with 150 µL of anti-goat blocking serum (1 drop goat serum to 3.33mls PBS as 
indicated in protocol by Vector Laboratories).  Blocking serum was removed by capillary 
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action using a Kimwipe™, and then each section was incubated at room temperature for 
one hour with 150 µL of rabbit polyclonal Ki67 antigen antibody (VPK451; Vector 
Laboratories, Inc., Burlingame, CA) at a dilution of 1:1,000.  For negative controls, each 
section was incubated at room temperature for one hour with 150 µL of rabbit anti-serum 
without primary antibody.  After incubation, each section was washed three times for five 
minutes each with 1x PBS, and then each section was incubated at room temperature for 
30 minutes with diluted ABC biotinylated secondary antibody solution (1 drop to 10mls 
PBS, Vector protocol).  Each section was then washed three times for five minutes each 
with 1x PBS and was incubated at room temperature for 30 minutes with VECTASTAIN 
elite ABC reagent (2 drops reagent A + 2 drops reagent B to 5 mL of 1x PBS, 30 minutes 
before addition to sections, Vector protocol).  Sections were then washed three times for 
five minutes each with 1x PBS.  To each section, diaminobenzidine (DAB) (Vector kit 
SK-4100) was applied and incubated for one minute until a pale brown color was visible 
and then immersed in deionized water and washed by constant flow with deionized water.  
Next, sections were immersed for two seconds into Mayer’s hematoxylin QS (Sigma 
Aldrich) and washed briefly in deionized water.  After washing, each section was 
immersed for one minute in Scott’s tap water substitute (3.5 g sodium bicarbonate and 20 
g magnesium sulfate/1L) to blue the nuclei.  Each section was dehydrated for one minute 
each in a graded series of increasing ethanol concentrations (95% 2x and 100% 2x).  
Each section was then immersed with three changes for one minute each of p-xylene.  
Permount was applied to each section before the addition of a coverslip.  After drying, 
each slide was observed at 300x with the Olympus BX 41 microscope attached to an 
Olympus DP70 camera.  Images were captured using DP control software and electronic 
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images saved by DP Manager.  Figure 3 displays a representative photo depicting how 
the luminal columnar epithelial height was quantified.  Measurements were calibrated 
using a grid from a hemacytometer.  Luminal columnar epithelial height (as depicted by 
vertical black line) was determined by an investigator “blinded” to the treatment groups 
using Image J software.  Measurements were performed in triplicate for each cross-
section, and an overall mean +/- SEM was calculated for each treatment group.              
   
Figure 3.  Representative image of a uterine cross-section depicting how luminal 
columnar epithelial height was measured.    
Li-Cor Odyssey
®
 with secondary infrared dyes  
The effect of the treatments on uterine proliferation was assessed by quantifying 
Ki67 expression.  Briefly, uterine cross-sections were obtained as described previously 
and then subjected to immunohistochemical analysis using 150 µL of rabbit polyclonal 
Ki67 antigen antibody (VPK451; Vector Laboratories, Inc., Burlingame, CA) at a 
dilution of 1:1,000.  Tissue sections were incubated for one hour at room temperature.  
For negative controls, each section was incubated at room temperature for one hour with 
150 µL of rabbit anti-serum without primary antibody.  After incubation, each section 
was washed three times for five minutes each with 1x PBS.  Each section was incubated 
at room temperature in the dark for 30 minutes with goat anti-rabbit secondary IRDye
®
 
Stroma 
Luminal columnar 
epithelium  
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800 CW (Li-Cor Biosciences, Lincoln, NE - #827-08365) at a dilution of 1:1,000.  Each 
section was allowed to air-dry.  After drying, each section was imaged with the Li-Cor 
Odyssey
®
 Infrared Imaging System and images were saved electronically.  The intensity 
of Ki67 expression was determined in the luminal columnar epithelium and stroma by the 
investigator “blinded” to the treatment group using Image J software.  Measurements 
were performed in triplicate for each cross-section, and an overall mean +/- SEM was 
calculated for each treatment group.  
Cytosol and nuclear preparation  
 Cytosol and nuclear preparation were performed according a protocol provided 
online by Millipore (Billerica, MA).  Frozen uterine cross-sections were homogenized 
with a Kontes Dounce Tissue Grinder that is designed to retain intact nuclei and dounced 
with ice-cold 400 µL RIPA buffer without detergents [50 mM Tris-HCl (pH 7.4), 140 
mM NaCl, 1 mM EGTA (pH 8.0), 1 mM PMSF, 1 µg/mL aprotinin, 1 µg/mL leupeptin, 
1 mM Na3VO4, 50 mM NaF, and 1 mM DTT].  The homogenates were centrifuged at 
2,900 g for 20 minutes at 4
o
C.  The supernatant (i.e., cytosolic and membrane fractions) 
was removed and then centrifuged at 29,000 g for 45 minutes at 4
o
C.  The supernatant 
from this centrifugation (i.e., cytosolic fraction) was removed and immediately stored at  
-20
o
C.   To the pellet obtained from the first centrifugation (i.e., the nuclear fraction), 250 
µL of ice-cold RIPA buffer containing 1% NP-40 was added.  The pellet was disrupted 
using a pipette tip, vortexed, and stored at -20
o
C.              
Western blot 
 The cytosolic and nuclear fractions from uterine tissues were thawed on ice.  
Cytosolic fractions were centrifuged at 10,000 g for two minutes to remove insoluble 
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proteins.  A BioRad DC Protein Assay (BioRad Laboratories, Hercules, CA) was 
performed according to manufacturer’s protocol.  An equal volume of Laemmli sample 
buffer (BioRad Laboratories) containing β-mercaptoethanol was added to each fraction 
and boiled in a water bath for ten minutes.  Proteins were separated using 7.5% Tris-HCl 
Ready Gels (BioRad Laboratories) submerged in running buffer (192 mM Glycine, 50 
mM Trizma Base, and 0.1% SDS).  Proteins were transferred to a PVDF membrane 
(BioRad Laboratories) submerged in ice-cold transfer buffer (192 mM Glycine, 25 mM 
Trizma Base, and 10% Methanol) at 90 V for 40 minutes.  The membrane was 
submerged in 100% methanol for 10 seconds, air-dried, and then incubated at 37
o
C for 
ten minutes.  After incubation, the membrane was submerged in 100% methanol for ten 
seconds and then in Nanopure water for one minute.  To reduce non-specific binding, 
each membrane was blocked at room temperature for one hour with blocking buffer (1x 
PBS, pH 7.4: 11.5 g Na2HPO4, 2.96 g NaH2PO4, and 5.84 g NaCl, 0.1% Tween 20 and 
4% nonfat milk) and then incubated at 4
o
C overnight with rocking in primary antibody 
containing either rabbit anti-estrogen receptor alpha (polyclonal estrogen receptor alpha; 
ab75635; Abcam; Cambridge, MA) or mouse anti-progesterone receptor (monoclonal 
PR-AT 4.14 to progesterone receptor; ab2764; Abcam) at a dilution of 1:8,000 (in 1x 
PBS containing 1% ECL Advance blocking agent; BioRad Laboratories).  The next day, 
the membrane was washed four times for five minutes each in 1x PBS.  The membrane 
was then incubated at room temperature for one hour with rocking in secondary antibody 
containing either ECL Anti-rabbit IgG, Horseradish peroxidase for ERα or ECL Anti-
mouse IgG, Horseradish peroxidase for PR (GE Biosciences UK limited, United 
Kingdom) at a dilution of 1:16,000 (in 1x PBS with 0.1% Tween 20 and 4% nonfat milk).  
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After incubation, the membrane was washed four times for five minutes each with 1x 
PBS.  In the dark, the blot was exposed to ECL Advance Western Blotting Detection 
System (GE Biosciences) diluted to 5% with water.  Protein bands were visualized with 
Amersham Hyperfilm ECL (GE Biosciences) at various time intervals (10 seconds to five 
minutes).  The protein bands were scanned electronically and quantified for mean 
intensity with Image J software.  Cytosolic proteins were normalized to GAPDH (rabbit 
polyclonal GAPDH; ab9485; Abcam).  An overall mean +/- SEM was calculated for each 
treatment group.  
Statistical analysis 
 Body weights, serum levels of E2 and P4, estrous cycling, mammary morphology, 
whole uterine wet weight, luminal columnar epithelial height, expression of Ki67 in 
luminal columnar epithelium and stroma, and ERα and PRA localization were analyzed 
by one-way analysis of variance (ANOVA) followed by Newman-Keuls multiple 
comparison post-hoc test with GraphPad Prism 5 software (GraphPad Software Inc., La 
Jolla, CA).  Significance was defined as p < 0.05 where (A), (B), and (C) represent 
significance as compared to Control, Melatonin, and EPRT, respectively.   
Real-time RT-PCR results were analyzed by an unpaired Student’s t-test or one-
way analysis of variance (ANOVA) followed by Dunnett's multiple comparison post-hoc 
test or Newman-Keuls post-hoc test with GraphPad Prism 5 software.  If the homogeneity 
of variances assumption was violated, a Dunnett’s C post-hoc follow-up test was 
performed with IBM Statistical Package for the Social Sciences (SPSS) version 20.  If the 
one-way ANOVA detected significant differences in both Melatonin and EPMRT groups, 
then a two-way ANOVA was performed using SPSS version 20 to investigate the main 
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effects of melatonin and E2 and P4.  Significance was defined as p < 0.05, p < 0.01, and 
p < 0.001 where (*), (**), and (***) represent significance to Control, respectively.   
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RESULTS   
EPMRT and other treatments did not affect body weight 
Each mouse was weighed before necropsy to determine if the treatments affected 
body weight.  The assessment of body weight is important to determine if the treatments 
affected food consumption or growth of the mice.  Moreover, melatonin has been 
demonstrated to reduce overall body weight in female BALBc and MMTV/activated Neu 
mice [117, 133].  Additionally, body weight was assessed as a means to standardize the 
uterine wet weight.  The results are presented in Figure 4.  Body weight was measured in 
grams.  Statistical analysis detected no significant differences among the four treatments 
suggesting that none of the treatments affected body weight. 
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Figure 4.  Treatment effects on body weight.  No significant differences were detected.  
Each bar represents mean ± SEM values from n = 18 - 19 mice per treatment group.  Data 
were analyzed by one-way ANOVA with significance defined as p < 0.05.   
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EPMRT and the other treatments did not affect serum levels of E2 and P4 
The pre-tumor study was conducted to gain insight into the anti-tumor effects of 
EPMRT [15].  Because E2 and P4 were blended into the food pellets, it was essential to 
determine if the treatments affected serum levels of E2 and P4.  The alterations in serum 
levels of E2 and P4 would provide an indication into the hormone environment of the 
mice which is necessary to understand and explain the findings from the tumor and pre-
tumor studies.  The results are presented in Figure 5.  Serum levels of E2 (in pg/mL) (Fig 
5A) and P4 (in ng/mL) (Fig 5B) were assessed in the three month old mice in estrus after 
one month of treatment.  Statistical analysis detected no significant differences among the 
four treatments for serum levels of E2 and P4 suggesting that none of the treatments 
affected the serum levels of E2 and P4. 
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Figure 5.  Treatment effects on serum levels of E2 and P4.  None of the treatments 
affected serum levels of (A) E2 and (B) P4.  Each bar represents the mean ± SEM values 
from n = 4 - 6 mice per treatment group for E2 and n = 7 - 8 mice per treatment group for 
P4 serum measurements.  Data were analyzed by one-way ANOVA with significance 
defined as p < 0.05.   
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EPMRT and EPRT increased the days in estrus and within an estrous cycle 
Even though the treatments did not affect the serum hormone levels of E2 and P4, 
the estrous cycling of the mice was measured as it may be more sensitive to subtle 
changes in serum E2 and P4 levels.  Additionally, the assessment of alterations in estrous 
cycling may be used to predict if the uterine microenvironment is being exposed to 
conditions that may lead to uterine proliferation.  In the tumor study, mice consuming 
EPRT had increases in uterine wet weight which was attenuated with the addition of 
melatonin (EPMRT).  Therefore, the assessment of estrous cycling may provide 
information about the early effects contributing to the increase in uterine wet weight 
observed in the tumor study.  To determine if the treatments altered estrous cycling, 
vaginal smears were performed daily for the 30 days of treatment.  The results are 
presented in Figure 6.   Treatment effects on estrous cycling were measured as:  A) the 
number of days in estrus over a 30-day period, B) the number of days in estrus per 
estrous cycle, C) the length of each estrous cycle, and D) the number of complete estrous 
cycles over a 30-day period.  Mice treated with EPRT or EPMRT had more days in estrus 
over 30 days (Fig 6A) as well as within a cycle (Fig 6B) as compared to Control and 
Melatonin-treated mice.  However, no differences occurred in the length of each estrous 
cycle (Fig 6C) or the total number of estrous cycles over a 30-day period (Fig 6D).  These 
results suggest that the hormone treatments, especially the E2 component, influenced the 
uterine environment of the mice.     
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Figure 6.  Treatment effects on estrous cycling.  Mice given either EPRT or EPMRT 
demonstrated increases (A) in the days in estrus over a 30-day period, and (B) in the 
number of days in estrus per estrous cycle compared to Control and Melatonin-treated 
mice.  However, no changes (C) in the length of each estrous cycle or (D) in the total 
number of estrous cycles over a 30-day period were detected.  Each bar represents the 
mean ± SEM from n = 18 - 20 mice per treatment group.  Data were analyzed by one-
way ANOVA followed by Newman-Keuls post-hoc test with significance defined as p < 
0.05.  A = p < 0.05 compared to Control; B = p < 0.05 compared to Melatonin. 
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EPMRT and the other treatments did not affect ductal elongation  
Beginning at about four weeks of age, the mammary gland is exposed to a surge 
of ovarian hormones to develop the mammary ductal network.  The rudimentary ductal 
tree begins to elongate into the fat pad, and this process is mediated by E2 actions at ERα 
[134-136].  To assess the extent of ductal elongation into the mammary fat pad, various 
measurements were performed on whole mounts of the inguinal mammary glands stained 
with carmine alum (see Figure 2).  Treatment effects on ductal elongation were measured 
as:  A) the length to end of gland (in mm) from the center of the lymph node and B) the 
length to end of duct (in mm) from the center of the lymph node.  Using these 
measurements, the extent of ductal elongation into the mammary fat pad was determined.  
The results are presented in Figure 7.  Statistical analysis detected no significant 
differences among the four treatments suggesting the extent of ductal elongation was 
similar for all the groups.  The ductal trees elongated into over 80% of the fat pat which 
is representative of a fully elongated ductal network.      
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Figure 7.  Treatment effects on ductal elongation into the mammary fat pad.  No 
significant differences in (A) mammary gland length, (B) ductal length, and (C) the 
extent of ductal elongation into the fat pad were detected.  Each bar represents the mean 
± SEM values from n = 6 - 7 mice per treatment group.  Data were analyzed by one-way 
ANOVA with significance defined as p < 0.05.  
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EPMRT and Melatonin induced tertiary side-branching 
As revealed in the tumor study, EPMRT increased tumor latency and decreased 
tumor incidence and weight when compared to Control [15].  Previous work by Russo 
and Russo 1998 demonstrated that mammary gland differentiation reduces the risk of 
breast cancer [137].  The initial stage in mammary gland differentiation is the formation 
of tertiary-side branches, and this process is mediated by P4 actions at PRA [136, 138-
140].  If EPMRT induces the formation of tertiary side-branching earlier in the process of 
ductal development, this may be a possible explanation for its protective actions against 
mammary cancer.  Figure 8A, B, C, and D display representative images of mammary 
gland whole mounts.  Qualitative increases in tertiary side-branching were observed in 
mammary glands from mice treated with EPMRT or Melatonin.  Therefore, we 
investigated whether or not these treatments induced tertiary side-branching compared to 
Control by quantifying the number of tertiary side-branches (per mm
2
) in mammary 
gland whole mounts stained with carmine alum.  The results are presented in Figure 8E.  
Statistical analysis detected significant increases in tertiary side-branching in mice treated 
with EPMRT or Melatonin with melatonin having a main effect indicating that melatonin 
is inducing tertiary side-branching.  The protective actions of EPMRT against mammary 
cancer may be through promoting the initial stage of mammary differentiation earlier in 
the process of ductal development.     
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A.  Control 
B.  Melatonin 
D.  EPMRT 
C.  EPRT 
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Figure 8.  Treatment effects on tertiary branching in mammary glands.   Representative 
images of mammary gland whole mounts displaying the extent of tertiary branching for 
each group: A) Control, B) Melatonin, C) EPRT, and D) EPMRT.  (E) Quantification of 
stained glands for tertiary branching was performed for each group.  Mammary ducts of 
mice treated with EPMRT or Melatonin had significantly more tertiary side-branches as 
compared to the Control group.  Each bar represents the mean ± SEM values from n = 6 - 
7 mice per treatment group.  Data were analyzed by one-way ANOVA followed by 
Newman-Keuls post-hoc test with significance defined as p < 0.05.  Two-way ANOVA 
revealed a significant main effect for melatonin, p < 0.001, but not for E2 and P4, p = 
0.88.  A = p < 0.05 compared to Control.  Scale bar set at 2 mm (left panels, 
magnification = 13x) and at 1 mm (right panels, magnification = 26x).    
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Detection of melatonin receptors in mammary glands of Control mice 
Because melatonin induced tertiary side-branching, investigations were performed 
to assess if the mammary gland expresses melatonin receptors.  Melatonin can produce 
effects through melatonin receptor subtypes, MT1 and MT2, and can also elicit actions 
independent of these receptors.  Therefore, the detection of melatonin receptor expression 
is important to help determine if the effects of melatonin may be occurring through 
melatonin receptor-dependent pathways.  To determine if melatonin receptors are present 
in the mammary tissue, total binding assays were performed using the 2-[
125
I] 
iodomelatonin radioligand in Control mice.  The results are presented in Table 2.  
Mammary tissues of Control mice expressed low levels of receptor, 7.8 ± 2.8 fmoles/mg 
protein.  Because of the non-selective nature of the radioligand, real-time RT-PCR was 
performed to assess for levels of melatonin receptor mRNA.  The determination of 
melatonin receptor protein expression by western blot analysis or tissue distribution (i.e., 
epithelial or adipose) by immunohistochemisty could not be performed due to lack of a 
well-characterized and field-accepted primary antibodies for these receptors.  The results 
of the real-time RT-PCR analysis indicated that MT2 receptor mRNA (i.e., Mtnr1b) was 
detected in the mammary tissue in four of the six mice tested; however, no MT1 receptor 
mRNA (i.e., Mtnr1a) was detected.  In contrast to the real-time RT-PCR data, the results 
of the microarray analysis may suggest the presence of Mtnr1a mRNA.  These data 
indicate that the expression of the melatonin receptors is low, and, in the mammary 
glands, the MT2 receptor is the primary melatonin receptor subtype expressed.  However, 
the possibility of MT1 receptor expression was not excluded.  These results suggest that 
the protective actions of EPMRT on mammary tumorigenesis and the effects of 
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melatonin on mammary differentiation may be attributed, in part, to the actions of 
melatonin at MT2 receptors in the mammary gland.   
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Microarray results 
Official Symbol  Accession #   Title (Designation)      Entrez Gene ID   FcMel   FcEPRT   FcEPMRT        
Mtnr1a  NM_008639   melatonin receptor 1A           17773             1.185        1.11            1.41  
Mtnr1b  NM_145712   melatonin receptor 1B           244701           -1.10        -1.11           -1.00 
 
Table 2.  Expression of melatonin receptors in mammary tissue of Control mice.  
Melatonin receptor expression was assessed using 500pM 2-[
125
I] iodomelatonin on 
membrane preparations from Control mammary tissue (n = 8).  RNA was prepared from 
mammary tissues from six Controls and subjected to microarray and real-time RT-PCR 
analyses.  Real-time RT-PCR analysis detected MT2 but not MT1 receptor mRNA.  
However, microarray analysis may indicate a presence of MT1 receptor mRNA.  Fc = 
fold change versus Control where as positive number indicates an increase in melatonin 
receptor mRNA expression while a negative number indicates a decrease in mRNA 
expression.  
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EPMRT synergistically altered gene expression in the mammary gland 
To investigate if the protective actions of EPMRT on mammary tumorigenesis 
may occur through alterations in gene expression, microarray analysis was used to 
identify those genes differentially expressed in the mammary gland following EPMRT 
treatment compared to the Control group.  To address this question, three pools of total 
RNA (i.e., two mice per pool from each group) from mammary tissue for each treatment 
group (Control, Mel, EPRT, and EPMRT) were subjected to microarray analysis.  Genes 
induced by ≥ 1.5 fold or repressed by ≤ -1.5 fold compared to Control were considered as 
potential candidates to be further analyzed by real-time RT-PCR.  The results are 
presented in Figure 9.  Melatonin induced 14 genes, EPRT induced 123 genes, and 
EPMRT induced 204 genes.  Also, Melatonin repressed 16 genes, EPRT repressed 10 
genes, and EPMRT repressed 713 genes.  EPMRT altered gene expression to a greater 
extent as compared to the other groups with most of the actions of EPMRT being through 
gene repression.  These results suggest that melatonin in combination with E2 plus P4 
(EPMRT) synergistically altered gene expression in the mammary gland.           
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Figure 9.  Treatment effects on gene expression in mouse mammary glands.  Fold change 
(Fc) values are expressed by treatment group and compared to Control.  EPMRT altered 
gene expression to a greater extent as compared to the other groups with most of the 
actions of EPMRT being through gene repression.  Data are expressed as total number of 
genes induced (Fc values ≥ 1.5) or repressed (Fc values ≤ -1.5) for each treatment, n = 3 
pools per treatment group.  
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Venn diagram of the genes with altered expression  
 To further identify those genes with expression uniquely altered by EPMRT 
compared to Melatonin or EPRT, a Venn diagram was created to assess the relationships 
of these genes for each of the treatments.  The results are presented in Figure 10.    
EPMRT altered exclusively 827 genes and co-regulated 69 and 13 genes with EPRT and 
Melatonin, respectively.  These genes may underlie the protective actions of EPMRT on 
mammary tumorigenesis.     
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Figure 10.  Venn diagram displaying the number of genes with altered expression for 
each of the treatments.  EPMRT altered exclusively 827 genes and co-regulated 69 and 
13 genes with EPRT and Melatonin, respectively.  Data expressed in the Venn diagram 
represent the total number of genes with altered expression that were induced (Fc values 
≥ 1.5) or repressed (Fc values ≤ -1.5) compared to Control with n = 3 [3 pools; 2 mice per 
pool per treatment group].      
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EPMRT and the other treatments did not alter the expression of rat Erbb2, Krt18, 
and Ms1a4 mRNA 
 Before beginning the process of confirming the microarray data by real-time RT-
PCR, tissue samples were analyzed to confirm that the samples were from epithelial-
enriched regions of the mammary gland and free of lymph node contamination.  
Moreover, it was important to assess if the treatments did not influence the expression of 
the rat Erbb2 transgene which could affect tumorigenesis by regulation at the MMTV 
promoter.  To determine if the selected tissue samples were from epithelial-enriched 
regions and not from adipose-enriched areas, the levels of Krt18 mRNA, a gene encoding 
the epithelial cell marker, keratin 18, were assessed.  To determine if the RNA samples 
were free of lymph node contamination, levels of Ms1a4 mRNA, the gene encoding B-
lymphocyte antigen CD20, were assessed.  This assessment was important to ensure that 
the mRNA in the sample was not diluted by the mRNA from the lymph node, thereby 
affecting the mRNA levels of the candidate genes.  Treatment effects were assessed by 
determining the change in threshold cycle (∆Ct).  A higher ∆Ct value indicates lower 
gene expression and a lower ∆Ct value indicates higher gene expression.  The results are 
presented in Figure 11.  Statistical analysis detected no significant differences among the 
four treatments suggesting that the tissue samples expressed similar levels of rat Erbb2, 
Krt18, and Ms4a1 mRNA among the treatments.  Because a higher ∆Ct value indicates 
lower gene expression and a lower ∆Ct value indicates higher gene expression, the results 
suggest that the tissue samples were from epithelial-enriched regions and did not contain 
lymph node tissue.  The results also suggest that the levels of transgene mRNA were not 
altered by the treatments.  
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Official Symbol    Accession #       Title (Designation)            Entrez Gene ID          
Erbb2    NM_001003817       v-erb-b2 erythroblastic leukemia                 24337   
                       viral oncogene homolog 2 
Krt18    NM_010664       keratin 18                     16668    
Ms4a1    NM_007641       membrane spanning 4-domains,                   12482   
          subfamily A, member 1,  
          B-lymphocyte antigen CD20 
 
Figure 11.  Treatment effects on the expression of rat Erbb2, Krt18, and Ms4a1 mRNA.  
Analysis revealed that the tissue samples expressed similar levels of (A) rat Erbb2, (B) 
Krt18, and (C) Ms4a1 mRNA among the groups.  Each bar represents the mean ∆Ct ± 
SEM values from n = 5 - 7 mice per treatment group.  Data were analyzed by one-way 
ANOVA with significance defined as p < 0.05.   
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Selection of candidate genes  
To select candidate genes for further investigation by real-time RT-PCR, the 
Entrez Gene summaries were visually scrutinized for each gene regulated by EPMRT.  A 
list of candidate genes was compiled based on if the genes were hormone-regulated, 
growth-promoting, related to cell differentiation, or involved in tumorigenesis, in general.  
The candidate genes are presented in Table 3.  The final selection of candidate genes 
included hormone regulated genes, Areg, Esr1, Greb1, Per2, and Pgr; growth-promoting 
genes, Adra1a, Akr1c14, Areg, Esr1, Figf, Greb1, and Pgr; genes involved with cell 
differentiation, Csn1s2a, Esr1, Pgr, and St3gal5; and genes involved with tumorigenesis, 
Duox1, Figf, Greb1, Ido1, Lcn2, Per2, Ptprd, and Slc24a3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
Official Symbol    Accession #    Title (Designation)          Entrez Gene ID          
Adra1a    NM_013461    adrenergic receptor, alpha 1a               11549  
Akr1c14    NM_134072    aldo-keto reductase family 1, member C14              105387   
Areg    NM_009704    amphiregulin                 11839 
Csn1s2a    NM_007785    casein alpha s2-like                12993  
Duox1    NM_001099297    dual oxidase 1                 99439  
Esr1    NM_007956    estrogen receptor 1, alpha               13982   
Figf    NM_010216    c-fos induced growth factor               14205  
       vascular endothelial growth factor D (VEGF-D) 
Greb1    NM_015764    gene regulated by estrogen in                268527  
       breast cancer protein    
Ido1    NM_008324    indoleamine 2, 3-dioxygenase 1               15930  
Lcn2    NM_008491    lipocalin 2                 16819   
Per2    NM_011066    period homolog 2, Drosophila               18627  
Pgr    NM_008829    progesterone receptor                18667   
Pgr [Pgr(A)]       progesterone receptor A    
Ptprd    NM_001014288   protein tyrosine phosphatase,                19266  
       receptor type D   
Slc24a3    NM_053195    solute carrier family 24 member 3              94249   
       sodium/potassium/calcium exchanger   
St3gal5    NM_011375    ST3 beta-galactoside alpha               20454  
       -2, 3-sialyltransferase 5  
 
Table 3.  Selected candidate genes for real-time RT-PCR analysis. 
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Functional annotation clustering of selected candidate genes 
The online Database for Annotation, Visualization and Integrated Discovery 
(DAVID) Bioinformatics Resources 6.7 was used to generate a comprehensive clustering 
set of functional annotations (i.e., biological functions) to provide an understanding of the 
biological meaning behind the candidate genes.  The hypothesis behind the grouping 
algorithm is that similar annotations should have similar gene members.  Therefore, 
functional annotation clustering was performed to group these similar annotations 
together to determine the role of the genes in biological functions.  The results of the 
clustering are presented in Table 4.  An annotation cluster consisted of a grouping of 
biological functions due to sharing similar genes.  The genes were grouped into seven 
clusters [141, 142].      
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Annotation Cluster 1 Genes Count 
Branching involved in mammary gland 
duct morphogenesis 
Areg, Esr1, Pgr 3 
Mammary gland duct morphogenesis Areg, Esr1, Pgr 3 
Mammary gland morphogenesis Areg, Esr1, Pgr 3 
Female sex differentiation Areg, Esr1, Pgr 3 
Gland morphogenesis Areg, Esr1, Pgr 3 
Mammary gland development Areg, Esr1, Pgr 3 
Branching morphogenesis of a tube Areg, Esr1, Pgr 3 
Epithelial tube morphogenesis Areg, Esr1, Pgr 3 
Morphogenesis of a branching structure Areg, Esr1, Pgr 3 
Sex differentiation Areg, Esr1, Pgr 3 
Tube morphogenesis Areg, Esr1, Pgr 3 
Morphogenesis of an epithelium Areg, Esr1, Pgr 3 
Gland development Areg, Esr1, Pgr 3 
Tissue morphogenesis Areg, Esr1, Pgr 3 
Reproductive developmental process Areg, Esr1, Pgr 3 
Tube development Areg, Esr1, Pgr 3 
Epithelium development Areg, Esr1, Pgr 3 
Annotation Cluster 2   
Response to organic substance Adra1a, Areg, Duox1, Esr1, Ido1 5 
Response to hormone stimulus Adra1a, Areg, Esr1 3 
Response to endogenous stimulus Adra1a, Areg, Esr1 3 
Growth Adra1a, Areg, Esr1 3 
Annotation Cluster 3   
Glycoprotein Adrala, Areg, Figf, Esr1, Lcn2, Ptprd, Slc24a3, 
St3gal5 
8 
Disulfide bond Areg, Figf, Csn1s2a, Lcn2, Ptprd, Slc24a3 6 
Glycosylation site: N-linked (ClcNAc…) Adra1a, Areg, Figf, Lcn2, Ptprd, Slc24a3, St3gal5 7 
Annotation Cluster 4   
Signal Areg, Figf, Csn1s2a, Lcn2, Ptprd, Slc24a3 6 
Signal peptide Areg, Figf, Csn1s2a, Lcn2, Ptprd, Slc24a3 6 
Extracellular region Areg, Figf, Csn1s2a, Lcn2 4 
Secreted Figf, Csn1s2a, Lcn2 3 
Annotation Cluster 5   
Regulation of cell proliferation Figf, Esr1, Ido1, Pgr 4 
Transition metal ion binding Duox1, Esr1, Ido1, Pgr 4 
Metal ion binding  Duox1, Esr1, Ido1, Pgr, Slc24a3 5 
Cation binding  Duox1, Esr1, Ido1, Pgr, Slc24a3 5 
Ion binding Duox1, Esr1, Ido1, Pgr, Slc24a3 5 
Metal-binding Esr1, Ido1, Pgr 3 
Annotation Cluster 6   
Rhythmic process Esr1, Per2, Pgr 3 
Transcription regulation Esr1, Per2, Pgr 3 
Transcription Esr1, Per2, Pgr 3 
Regulation of transcription, DNA-
dependent 
Esr1, Per2, Pgr 3 
Regulation of RNA metabolic process Esr1, Per2, Pgr 3 
Regulation of transcription Esr1, Per2, Pgr 3 
Nucleus Esr1, Per2, Pgr 3 
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Annotation Cluster 7 
Transmembrane Adra1a, Areg, Duox1, Greb1, Ptprd, Slc24a3, 
St3gal5 
7 
Transmembrane region Adra1a, Areg, Greb1, Ptprd, Slc24a3, St3gal5 6 
Membrane Adra1a, Areg, Duox1, Greb1, Ptprd, Slc24a3, 
St3gal5 
7 
Integral to membrane Adra1a, Areg, Duox1, Greb1, Ptprd, Slc24a3, 
St3gal5 
7 
Intrinsic to membrane Adra1a, Areg, Duox1, Greb1, Ptprd, Slc24a3, 
St3gal5 
7 
Topological domain: Cytoplasmic Adra1a, Ptprd, Slc24a3, St3gal5 4 
Topological domain: Extracellular Adra1a, Ptprd, Slc24a3 3 
Not Clustered   
Cell proliferation Areg, Esr1, Figf 3 
Oxidation reduction Akr1c14, Duox1, Ido1 3 
Receptor Adra1a, Esr1, Pgr, Ptprd 4 
Phosphoprotein Adra1a, Csn1s2a, Esr1, Per2, Pgr, Ptprd, St3gal5 7 
Plasma membrane Adra1a, Esr1, Slc24a3 3 
 
Table 4.  Functional annotation clustering of the genes.  A DAVID analysis was 
conducted on the selected candidate genes to determine the functional annotation 
clustering of the genes.  An annotation cluster consisted of a grouping of biological 
functions due to sharing similar genes.  The genes were grouped into seven clusters.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
EPMRT decreased expression of Areg, Ido1, and Pgr(A) mRNA 
Based on the results of the tumor study, and the effects on gene expression by 
EPMRT, real-time RT-PCR analysis was performed on the selected candidate genes to 
confirm whether or not EPMRT altered the expression of these genes compared to 
Control.  Real-time RT-PCR is a method used to validate results obtained from 
microarray analysis by quantifying changes in gene expression.  Treatment effects were 
assessed by determining the change in threshold cycle (∆Ct).  A higher ∆Ct value 
indicates lower gene expression and a lower ∆Ct value indicates higher gene expression. 
The results are presented in Figure 12.  Statistical analysis detected significant decreases 
in the levels of Areg, Ido1, and Pgr(A) mRNA compared to Control.  Areg encodes 
amphiregulin, an epidermal growth factor receptor 1 (ERBB1) ligand; Ido1 encodes 
indoleamine 2, 3-dioxygenase, an immunosuppressive enzyme that impairs antigen-
dependent T-cell activation thereby promoting tumor tolerance; and Pgr(A) encodes 
PRA, a receptor involved in mammary epithelial cell proliferation and differentiation.  By 
contrast, a trend towards a significant increase was detected for Csn1s2a, p = 0.06.  
Csn1s2a encodes casein alpha s2-like, a marker of ductal differentiation.  Therefore, 
these results suggest that EPMRT significantly modulated genes in a manner that may be 
protective against mammary cancer.    
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Figure 12.  The effect of EPMRT on expression of selected candidate genes in mammary 
tissue compared to Control.  The levels of Areg, Ido1, and Pgr(A) mRNA were 
significantly decreased compared to Control.  A trend towards a significant increase was 
detected for Csn1s2a, p = 0.6.  Each bar represents the mean ∆Ct ± SEM values from n = 
5 - 7 mice in Control or EPMRT groups.  Value inside the bar represents fold change of 
expression as determined by the 2
-ΔΔCt 
method.  Data were analyzed by unpaired 
Student’s t-test with significance defined as p < 0.05 with (*) = p < 0.05 and (**) = p < 
0.01.  A higher ∆Ct value indicates lower mRNA expression.   
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Treatments decreased expression Areg, Ido1, and Pgr(A) mRNA  
 In order to ascertain whether the decreases in the levels of Areg, Ido1, and  Pgr(A) 
mRNA following EPMRT exposure were unique to EPMRT, real-time RT-PCR analysis 
was performed using mammary tissue samples from the Melatonin and EPRT groups.  
Treatment effects were assessed by determining the change in threshold cycle (∆Ct).  A 
higher ∆Ct value indicates lower gene expression and a lower ∆Ct value indicates higher 
gene expression.  The results are presented in Figure 13.  Statistical analysis detected 
significant differences among the four treatments for these genes.  Mammary tissue from 
mice treated with Melatonin or EPMRT had significantly decreased levels of Areg and 
Pgr(A) mRNA compared to Control (Figs. 13A and 13C) with further analysis indicating 
a significant main effect for melatonin.  The levels of Ido1 mRNA were significantly 
decreased in mammary tissue from mice given EPMRT compared to Control (Fig 13B) 
suggesting that melatonin in combination with E2 plus P4 repressed gene expression.   
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Figure 13.  Treatment effects on the expression of Areg, Ido1, and Pgr(A) mRNA in 
mammary tissue.  (A) The levels of Areg mRNA were significantly decreased in 
mammary tissue from mice given Melatonin or EPMRT compared to Control.  (B) The 
levels of Ido1 mRNA were significantly decreased in mammary tissue from mice given 
EPMRT compared to Control.  (C) The levels of Pgr(A) mRNA were significantly 
decreased in mammary tissue from mice given Melatonin or EPMRT compared to 
Control.  Each bar represents the mean ∆Ct ± SEM values from n = 5 - 7 mice per 
treatment group.  Value inside the bar represents fold change of expression as determined 
by the 2
-ΔΔCt 
method.  Data were analyzed by one-way ANOVA followed by Dunnett’s 
post-hoc test (A and B) or by Dunnett’s C (C) with significance defined as p < 0.05 with 
(*) = p < 0.05.  (A and C) Two-way ANOVA revealed a significant main effect for 
melatonin, p < 0.05, but not for E2 and P4, p = 0.31 and p = 0.72, respectively.  A higher 
∆Ct value indicates lower mRNA expression.   
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Predicted protein association networks for amphiregulin and indoleamine 2, 3-
dioxygenase  
The online database resource Search Tool for the Retrieval of Interacting Genes 
(STRING) 9.05 was used to generate predicted protein – protein interactions of 
amphiregulin and indoleamine 2, 3-dioxygenase in the mouse.  The STRING 9.05 
database consists of known and predicted proteins derived from a variety of sources and 
then quantitatively integrates interaction data to generate an association network.  These 
protein networks provide an opportunity to view a genome more dynamically as 
compared to a collection of functions.  [143, 144].         
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Predicted protein – protein interactions of amphiregulin  
 
Egfr epidermal growth factor receptor 
Ptgs2 prostaglandin-endoperoxide synthase 2 
Akt1 thymoma viral proto-oncogene 1 
Pgr progesterone receptor 
Mapk14 mitogen-activated protein kinase 14 
Pthlh parathyroid hormone-like peptide 
Atf3 activating transcription factor 3 
Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 
Errb3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 
Cnih cornichon homolog (Drosophila) 
 
Figure 14.  Predicted protein – protein interactions of amphiregulin.  The online database 
resource STRING 9.05 was used to generate predicted protein – protein interactions of 
AREG.  STRING quantitatively integrates interaction data to generate an association 
network.   
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Predicted protein – protein interactions of indoleamine 2, 3-dioxygenase  
 
Kynu kynureninase (L-kynurenine hydrolase) 
Ifng interferon gamma 
Afmid arylformamidase 
Tph1 tryptophan hydroxylase 1 
Il4i1 interleukin 4 induced 1 
Bin1 bridging integrator 1 
Wars tryptophanyl-tRNA synthetase 
Maoa monoamine oxidase A 
Il6 interleukin 6 
Aanat arylalkylamine N-acetyltransferase 
 
Figure 15.  Predicted protein – protein interactions of indoleamine 2, 3-dioxygenase.  
The online database resource STRING 9.05 was used to generate predicted protein – 
protein interactions of IDO1.  STRING quantitatively integrates interaction data to 
generate an association network.   
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EPMRT and EPRT did not affect uterine wet weight 
 In the long-term tumor study, mice treated with EPRT, beginning at two months 
of age and continuing until 14 months of age, resulted in an increase in uterine wet 
weight.  This finding was expected because of the lower dose of P4; therefore, the anti-
proliferative actions of P4 on E2-mediated endometrial proliferation would be attenuated.  
We hypothesized that the addition of melatonin to EPRT would provide uterine 
protection through changes in P4 and PR levels.  To attempt to explain why EPRT 
increased uterine wet weight while EPMRT had no effect, mice were exposed to these 
same treatments for 30 days, and the effects on the uterus were assessed.  Specifically, 
treatment effects on uterine wet weight, luminal epithelial cell height, and endometrial 
proliferation were examined.  Uterine wet weight was standardized to body weight 
(mg/g).  The results are presented in Figure 16.  Statistical analysis revealed no 
significant differences among the four treatments suggesting that, unlike the results from 
the tumor study, EPRT did not promote an increase in uterine wet weight following 30 
days of treatment.   
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Figure 16.  Treatment effects on uterine wet weight standardized to body weight.  No 
significant differences were detected.  Each bar represents the mean ± SEM values from 
n = 13 - 15 mice per treatment group.  Data were analyzed by one-way ANOVA with 
significance defined as p < 0.05.   
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EPRT did not induce hypertrophy of the luminal columnar epithelium 
In this 30 day pre-tumor study, mice treated with either EPRT or EPMRT 
demonstrated an increase in the number of days in estrus and the number of days in estrus 
per estrous cycle compared to Control.  An increase in estrus may indicate an increase in 
E2 exposure on uterine tissues that may increase the E2-mediated proliferative effects in 
the endometrium, as well as induce hypertrophy of the luminal epithelium.  Assessments 
of the hormones known to influence the uterus may help to explain the tumor study 
findings demonstrating that female mice given EPRT for one year had enlarged uteri and 
when melatonin was added in combination with E2 plus P4 this enlargement was 
attenuated.  Figures 17A, B, C, and D display representative images of uterine cross-
sections, and the black arrows denote the luminal columnar epithelium in each image.  
No increases in luminal epithelial height were qualitatively observed in the uterine cross-
sections.  In order to determine whether or not the treatments, especially EPRT, resulted 
in uterine epithelial cell hypertrophy, measurements of the luminal columnar epithelial 
height were performed on uterine tissue cross-sections taken from mice in estrus per 
treatment group.  The results are presented in Figure 17E.  Statistical analysis detected no 
significant differences among the four treatments suggesting that the treatments did not 
induce hypertrophy of the luminal epithelium beyond what occurs in mice during in 
estrus.       
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Figure 17.  Treatment effects on hypertrophy of the luminal columnar epithelium.   
Representative images of uterine cross-sections for each group: A) Control, B) 
Melatonin, C) EPRT, and D) EPMRT.  Black arrows denote the luminal columnar 
epithelium in each image.  (E) No significant differences were detected.  Each bar 
represents the mean ± SEM values from n = 6 - 9 mice per treatment group.  Data were 
analyzed by one-way ANOVA with significance defined as p < 0.05.   
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EPRT did not increase endometrial proliferation  
 Even though mice treated with either EPRT or EPMRT for 30 days demonstrated 
no changes in uterine wet weight, the length of time in estrus was increased in mice 
exposed to these treatments.  Because estrus is characterized by increased estrogen levels, 
this may enhance excessive endometrial proliferation.  To investigate if EPRT or EPMRT 
induced excessive endometrial proliferation, uterine cross-sections from each of the four 
groups were probed with an antibody against Ki67, a protein marker of DNA synthesis.  
The intensity of Ki67 expression was assessed in both regions comprising the uterine 
endometrium (i.e., luminal epithelium and stroma).  The results are presented in Figure 
18.  Statistical analysis detected no significant differences among the four treatments for 
Ki67 expression in the luminal epithelium or stroma suggesting that neither EPRT nor 
EPMRT increased endometrial proliferation during the 30 days of treatment even though 
these mice spent more time in estrus.        
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Figure 18.  Treatment effects on endometrial proliferation.  The intensity of Ki67 
expression in the (A) luminal epithelia and (B) stroma was determined.  No significant 
differences were detected.  Each bar represents the mean ± SEM from n = 7 - 10 mice per 
treatment group.  Data were analyzed by one-way ANOVA with significance defined as p 
< 0.05.   
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Melatonin increased uterine expression of ERα and PRA 
 Modulations of ERα and PRA expression in the uterus by the treatments may 
provide important early molecular indicators as to why EPRT treatment for over one year 
increases uterine weight, and how the addition of melatonin blocks this from occurring.  
In this study, cellular fractions were obtained from uterine cross-sections in order to 
assess the expression levels of ERα and PRA by western blot analysis.  The results are 
presented in Figure 19.  Statistical analysis detected significant differences among the 
four treatments.  Mice treated with Melatonin had significantly increased nuclear 
expression of ERα and cytosolic expression of PRA in the uterus.  The expression levels 
of these receptors were unchanged in the other groups compared to Control; however, the 
cytosolic expression of PRA remained elevated in mice treated with EPMRT.     
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Figure 19.  Treatment effects on uterine expression of ERα and PRA.  Mice treated with 
Melatonin had significantly increased (A) nuclear expression of ERα and (B) cytosolic 
expression of PRA in the uterus.  The expression levels of these receptors were 
unchanged in the other groups compared to Control; however, the cytosolic expression of 
PRA remained elevated in mice treated with EPMRT.  Each bar represents the mean ± 
SEM from n = 4 - 7 mice per treatment group.  Data were analyzed by one-way ANOVA 
followed by Newman-Keuls post-hoc test with significance defined as p < 0.05.  A = p < 
0.05 compared to Control; B = p < 0.05 compared to Melatonin.    
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DISCUSSION 
The results of this 30-day pre-tumor study provide important insight into the 
protective actions of EPMRT against the development, growth, and progression of 
mammary cancer while protecting the uterus from excess estrogen exposure in the 
MMTV/unactivated Neu mouse model.  Because novel HRTs need to be developed for 
women experiencing menopausal symptoms without increasing their risk of breast 
cancer, these studies are imperative in order to advance the future use of EPMRT in this 
population.   
In this study, we demonstrated that EPMRT had no effect on body weight and 
serum levels of P4 and E2.  In the mammary gland, specific melatonin binding sites were 
detected by radioligand binding analysis, and real-time RT-PCR analysis detected 
expression of MT2 receptor mRNA.  The ductal trees of the mammary glands were fully 
elongated in all groups; but, melatonin induced tertiary side-branching, an initial stage of 
ductal differentiation.  Moreover, EPMRT differentially regulated gene expression in a 
synergistic manner compared to Control, and further analysis by real-time RT-PCR 
revealed decreases in expression of Areg, Ido1, and Pgr(A) mRNA.  EPMRT increased 
the number of days in estrus as well as increased the number of days in estrus per estrous 
cycle without affecting the length and number of estrous cycles.  However, these 
increases by EPMRT produced no changes in uterine wet weight, luminal epithelial 
height and endometrial proliferation.  Moreover, treatments containing melatonin 
increased cytosolic localization of the PRA which may protect the uterus from excessive 
estrogen exposure over time.      
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The WHI demonstrated that PREMPRO
®
 increased the risk of breast cancer [6, 
10] suggesting that the progestogen component of the replacement therapy contributed to 
the increase in breast cancer and mortality [41].  Our approach was to lower the daily 
dose of P4 from the clinically recommended dose of 100 mg to 50 mg, because it was 
hypothesized that lowering the dose of the progestogen component will protect against 
mammary cancer; however, the reduction in the dose of P4 may not protect the uterus 
from excessive estrogen exposure.  Therefore, melatonin was added to this therapy to 
provide additional protection against mammary cancer and to prevent excessive 
endometrial proliferation that could occur with an unbalanced E2 plus P4 therapy.  
Melatonin was added to the drinking water during the hours of darkness because previous 
studies using nocturnal, and not daytime, administration of melatonin via drinking water 
demonstrated effectiveness in preventing chemically- (i.e., dimethylbenzanthracene) and 
non-chemically-induced mammary carcinogenesis in rodents [88, 117]. 
Our experimental design utilized non-ovariectomized MMTV/unactivated Neu 
mice to mimic HRT usage in perimenopausal women who maintain ovarian function 
throughout this stage of their life and who would be ideal candidates for HRT.  Also, in 
this mouse model, E2 is essential for tumor development [117, 145-147] as well as to 
maintain PR expression in the mammary gland [148-151].  The mice were maintained on 
an isoflavone-free diet because exposure to isoflavones has been demonstrated to affect 
tumorigenesis in these mice.  Specifically, low-dose dietary isoflavones abrogated 
tamoxifen-associated mammary tumor prevention; high-dose dietary isoflavones fed to 
tamoxifen-treated mice resulted in longer tumor latency or no tumor formation by 60 
weeks [118].  Also, isoflavones in the diet may affect endogenous E2 levels because 
 88 
women with a diet rich in soy foods have significantly lower E2 serum concentrations 
[152, 153] through possible suppression of aromatase enzyme activity [154].   
EPMRT, as well as the other treatments, in this study had no effect on the body 
weight of the mice.  In contrast, Anisimov V.N. et al. 2003 reported that melatonin 
(nightly, 20 mg/L), given in drinking water for 30 days, slowed down body weight gain 
in MMTV/activated Neu mice (i.e., over-express the Neu oncogene) [117].  Daily food 
consumption was not monitored in our study; however, the mice in our study consumed 
about 3.5 mL of water per night consistent with reported consumption of 3.4 ± 1.0 mL of 
water per night for melatonin-treated MMTV/activated Neu mice [117].  Therefore, our 
results suggest that the treatments had no effect on weight gain as well as on feeding and 
drinking habits of the mice.    
The assessment of serum levels of E2 and P4 is imperative to gain information 
about the hormone exposures of the mice.  Changes in the hormonal levels, specifically in 
circulating E2 and P4, may influence ductal differentiation and gene expression in the 
mammary gland as well as proliferation in the uterus.  EPMRT and the other treatments 
did not impact serum hormone levels of E2 and P4 during estrus compared to Control.  It 
was hypothesized that the treatments could decrease endogenous levels of E2 and P4 via 
inhibition of the gonadotropic axis and/or inhibition of aromatase activity in the ovary.  
Perhaps the exogenous administration of E2 and P4 via the food pellets masked any 
changes in endogenous serum E2 and P4 levels and vice versa with endogenous changes 
masking the supplemented levels.  Another possibility was the changes in levels with the 
added hormones were not large enough to observe because of the normal variations in 
levels between individual mice.  Melatonin increased P4 production, decreased E2 
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biosynthesis in ovarian granulosa cells [103-107], and inhibited aromatase expression and 
activity [71, 155].  Based on our RT-PCR results, the addition of melatonin to E2 plus P4 
attenuated low dose P4 (25 mg)-induced Cyp19a1 expression, the gene encoding 
aromatase, in the ovary possibly through its actions on aromatase promoters (Appendix, 
Figure 20).   
Specific Aim 2 discussion 
Even though there were no significant changes in the serum levels of E2 and P4 
following administration of the treatments, other sensitive physiological process (i.e., 
estrous cycling, uterine epithelial height, proliferation, and ERα and PRA expression) 
regulated by E2 were examined.  An assessment of estrous cycling using cytological 
techniques was conducted to elucidate if the treatments altered normal cycling.  The 
length of the mouse estrous cycle is approximately four to five days and consists of four 
stages: 1) proestrus, 2) estrus, 3) metestrus, and 4) diestrus (see Figure 1) [129].  During 
the stages, E2 and P4 levels fluctuate.  During proestrus, E2 production increases with 
elevated levels persisting throughout estrus before production reduces with levels 
remaining relatively unchanged during metestrus and diestrus.  However, the level of P4 
begins to increase after estrus due to the secretion of P4 by the newly formed corpus lutea 
[129, 156, 157].     
  Increasing levels of estrogen and an increase in duration of exposure in the 
mammary gland and uterus to estrogen may stimulate mammary carcinogenesis and 
excessive endometrial proliferation, respectively.  Therefore, assessing alterations to the 
reproductive cycle may help to explain the protective actions of EPMRT as demonstrated 
in the tumor study.  The pre-tumor study revealed that EPRT and EPMRT increased the 
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number of days the mice spent in estrus over 30 days; however, the length and number of 
estrous cycles did not change over the same period of time.  These results were similar to 
Anisimov V.N. et al. 2003 who reported an average length of an estrous cycle of 5.5 ± 
0.31 days for Control mice and 6.38 ± 0.35 days for Melatonin-treated mice over 30 days.  
In our pre-tumor study, the Control and Melatonin mice had an average length of an 
estrous cycle of 6.10 ±1.28 days and 5.90 ± 1.18 days, respectively,   
One difference between our study and that of Anisimov V.N. et al. 2003 was the 
percentage of days each mouse spent in estrus per estrous cycle for Control and 
Melatonin.  In our study, the Control and Melatonin-treated mice were in estrus 36.1% 
and 34% of the time, respectively.  However, Anisimov V.N. et al. 2003 reported values 
of 45% for Control and 51% for Melatonin-treated mice [117].  These minor variations 
may be attributed to the different dose of melatonin (i.e., 15 mg/L versus 20 mg/L used 
by Anisimov et al.), the diets, or the housing conditions.    
The results indicated that Melatonin did not modify overall estrous function.  This 
was an unexpected finding because melatonin has been implicated in the seasonal 
reproductive behavior of some animals (e.g., sheep and hamsters) [158], that is dependent 
upon the environmental conditions [159].  Moreover, melatonin has been demonstrated to 
regulate the estrous cycle in felines [160] and has been tested for use as a birth control in 
women [161].  If melatonin was inhibiting estrogen synthesis and stimulating P4 levels in 
the ovary, the days in estrus was hypothesized to decrease while the time in diestrus was 
hypothesized to increase.  This effect was not observed in this study.  However, EPMRT 
and EPRT increased the days in estrus and per estrous cycle, but did not affect the length 
and number of estrous cycles.  The observed increase in the number of days in estrus 
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induced by EPRT may explain the overall increase in uterine wet weight observed in the 
tumor study possibly due to an increase in exposure of the endometrium to estrogens.  
The addition of melatonin to E2 plus P4 did not attenuate the EPRT-induced increase in 
days in estrus indicating that melatonin did not have an inhibitory effect within 30 days.  
Thus, the 30-day treatment period may not have been long enough to produce any 
measureable effects in the uterus.   
Even though no change in uterine wet weight was observed, the treatments may 
have affected uterine cell hypertrophy and/or proliferation.  To assess for changes in 
epithelial cell hypertrophy, the height of the luminal columnar epithelial cells was 
measured following immunohistochemical staining of uterine tissue cross-sections.  No 
observable or measurable changes in the height of these cells were detected across the 
treatments suggesting that the treatments, especially EPRT, did not induce hypertrophy of 
the luminal epithelium beyond what occurs in mice during in estrus.       
Although no treatment effects occurred on epithelial cell hypertrophy, the 
treatments, especially EPRT, may have increased endometrial proliferation.  Therefore, 
the expression of Ki67 in the luminal epithelium and the stroma, regions comprising the 
endometrium, was measured; an increase in Ki67 indicates a transition from G1 to the S 
phase of the cell cycle.  No changes in the expression levels of Ki67 in the luminal 
epithelium and the stroma occurred among the treatments suggesting that the treatments 
did not increase cellular proliferation.   
Even though there were no detectable changes in uterine weight, epithelial height, 
and proliferation by the treatments within 30 days, changes in the cellular ERα and PRA 
expression within the uterus may have occurred.  Therefore, if given enough time, the 
 92 
changes in ERα and PRA expression may have altered the sensitivity of uterine tissues to 
these hormones to result in the observed increases in the uterine wet weight in the tumor 
study.  Therefore, ERα and PRA levels in the uterus were assessed by western blot 
analysis.  Mice treated with Melatonin had significantly increased nuclear expression of 
ERα and cytosolic expression of PRA; however, the cytosolic expression of PRA 
remained elevated in mice treated with EPMRT.  Perhaps the increase in PRA expression 
in the uterus induced by melatonin underlies, in part, the protective actions of chronic 
EPMRT on uterine proliferation.  Progestogens, acting via PRs, inhibit E2-induced 
increases in uterine cell hypertrophy and proliferation [1].   
Specific Aim 1 discussion  
 In the mammary gland, the oncostatic effects of E2 and its metabolites include 
tumor initiation and promotion, regulatory control of genes, and cell proliferation.  
Estrogens regulate cancer-associated genes like Erbb2 (i.e., Neu) [162, 163] or induce 
transcriptional up-regulation, synthesis, and secretion of heregulin (HRG), epidermal 
growth factor (EGF), amphiregulin, and the EGFR [164-167].  An increase in cell 
proliferation enhances the probability of genotoxic events that produce genetic mutations 
[168-172].  Because E2 is known to influence tumorgenesis in this model, it was 
hypothesized that melatonin, through its anti-estrogen actions, would attenuate 
tumorigenesis induced either by endogenous estrogens or through EPRT by initiating 
differentiation, by repressing genes in the mammary gland known to be involved in 
mammary cancer, and by inducing genes known to be involved in mammary ductal 
differentiation.    
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The process of mammary ductal development is a complex, tightly regulated 
orchestration of growth, proliferation, and other cellular process in the course of a few 
weeks to create an adult ductal network.  In mice, this process begins at approximately at 
four weeks of age and concludes by eight weeks of age.  During this time, the mammary 
ducts develop from a rudimentary tree, through elongation of the ducts into the mammary 
fat pad, to be become a branched network of ducts.  Ductal elongation into the mammary 
fat pad occurs via the proliferation and differentiation of the epithelial progenitor cells in 
the terminal end buds located on the leading edge of the elongating ducts.  This process is 
mediated by E2 actions at ERα because mammary glands lacking ERα demonstrated 
impaired ductal growth [134-136].   
Ductal elongation in MMTV/unactivated Neu mice mammary glands may also be 
mediated by EGF signaling through ERBB1 receptors as evidenced by implantation of 
pellets containing EGF into estrogen-depleted mice initiated ductal growth [173].  The 
ERBB receptors influence cell proliferation, differentiation, development, and survival as 
well as being implicated with breast cancer tumorigenesis [174, 175].  The ERBB 
receptor belongs to the receptor protein tyrosine kinase superfamily that include ERBB1 
(i.e., EGFR), ERBB2 (i.e., NEU), ERBB3, and ERBB4.  Unlike the other family 
members, ERBB2 is an orphan receptor with no known endogenous ligand to initiate 
intracellular signaling.  For example, ERBB3 and ERBB4 bind heregulin (HRG) while 
ERBB1 binds EGF, TGF-α, and amphiregulin [176, 177].   
Amphiregulin is an EGFR/ERBB1 ligand that exists as a type 1 transmembrane 
protein in epithelial cells and extracellular cleavage produces the soluble ligand [178, 
179].  Ectodomain shedding of the protein is important for control of ligand availability 
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and activation of the EGFR [180].  The shedding allows amphiregulin to activate EGFR 
through paracrine and autocrine signaling.  Even in the absence of shedding, the 
membrane bound amphiregulin may activate the EGFR through juxtacrine signaling 
[177].   
 Estrogens are important activators of amphiregulin expression because estrogen, 
through ERα, induced amphiregulin expression.  This occurred through ERα binding to 
EREs on the gene [166] thus resulting in estrogen-induced expression in the breast [181].  
Amphiregulin has been demonstrated to be important during ductal growth where 
inactivation of the Areg gene in mice delays pubertal ductal elongation [179].  Levels of 
Areg mRNA increased in mammary glands of FVB mice between two to five weeks of 
age and remained elevated past five weeks.  Furthermore, these levels remained elevated 
into early pregnancy and then decrease sharply and remained low throughout lactation 
and involution [182].  Pregnancy, a time of increased mammary gland differentiation, 
may reduce the expression of amphiregulin.  For example, in situ hybridization studies 
revealed reduction of Areg expression in parous mammary epithelia [182].  Also, the 
expression of Areg was reduced after the first pregnancy in rats and was correlated with 
reduced tumorigenecity [182, 183].   
  Elevated levels of AREG mRNA has been implicated in the pathogenesis of 
breast cancer, and the protein is over-expressed in 35-50% of breast cancers [184-186].  
Hyperplastic enlarged lobular units (HELUs) are a common abnormality in breast tissue 
of adult women [187, 188].  Lee S. et al. 2007 reported an increase in AREG expression 
with a concomitant decrease in EGF expression in HELUs relative to terminal duct 
lobular units (TDLUs).  These results suggested that a reactivation of embryonic 
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development and a suppression of terminal differentiation could occur by switching 
EGFR ligand expression.  This switching of ligand expression could lead to different 
functional consequences [189].  Lastly, amphiregulin expression was increased in 
mammary tumors of transgenic mice over-expressing the Erbb2 oncogene [190].    
  We wanted to investigate if any of the treatments altered ductal elongation into 
the mammary fat pad because E2 is known to increase ductal elongation and melatonin, 
having anti-estrogenic properties, was hypothesized to decrease this process.  To explore 
this question, a quantitative assessment of ductal elongation was performed in carmine 
alum stained mammary glands.  The results revealed no significant differences on ductal 
elongation.  This result was in agreement with Mukjerjee S. et al. 2000 who reported that 
ductal elongation in MMTV/unactivated Neu mice was 93.3% ± 6.0 of the fat pad at 10 to 
15 weeks of age [151] similar to our results where ductal elongation in Control mice was 
86.6% ± 7.2 of the fat pad and 79.8% ± 7.7 to 92.7% ± 1.6 for the other treatments at 12 
weeks.  These data suggest that ductal elongation was concluded by the time of treatment 
exposure.  These results were also interesting because the levels of Areg mRNA were 
decreased in EPMRT-treated mice compared to Control.  Even though there were no 
significant differences in overall elongation among the treatments, the decrease in the 
levels of Areg mRNA by EPMRT may indicate a termination of ductal elongation, at the 
genetic level, thereby reducing the overall proliferative capacity of the ductals earlier 
than EPRT.  The decrease in levels of Areg mRNA at this time point by EPMRT may be 
contributing to the anti-tumor effects.        
  Differentiation of the mammary ducts in women contributes to the long-term 
decrease in breast cancer risk [137].  Melatonin induced differentiation in various cells 
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lines expressing melatonin receptors and through MAPK pathways [58, 59, 66, 78]; 
therefore, the addition of melatonin to E2 plus P4 may enhance the induction of ductal 
differentiation through these mechanisms.  However, melatonin may also induce ductal 
differentiation through effects on P4 and P4-mediated processes.  Once ductal elongation 
is complete, the ducts begin to arborize through development of tertiary side-branches, an 
early stage of mammary differentiation, with P4 signaling through PRA being necessary 
for this process [136, 138-140].  Specifically, PR-deficient mice have less extensive 
tertiary branching [191] while over-expression of PRA increased tertiary-side branching 
by 10 to 14 weeks of age [192].  P4-induced activation of signal transducer and activator 
of transcription 5a (STAT5a) may be important for induction of tertiary side-branching 
because mammary glands of STAT5a-/- mice demonstrate defects in tertiary side-
branching suggesting that Stat5a regulates this process [193].    
 To assess if the treatments induced tertiary side-branching, the number of tertiary 
side-branches in a given area were quantified in carmine alum stained post-pubertal 
mammary glands.  The mammary glands of the EPMRT and Melatonin groups 
demonstrated enhanced tertiary side-branching suggesting an overall melatonin effect 
because EPRT had no effect compared to Control.  Melatonin may be inducing tertiary 
side-branching through melatonin receptors and associated signaling cascades and/or 
through actions of melatonin on P4 synthesis and P4-mediated processes.   
 Regarding melatonin and melatonin receptors, melatonin binding sites have been 
detected in the mouse mammary gland [67] and other studies have demonstrated 
melatonin- and melatonin receptor-mediated effects on mammary gland development 
[133, 194] may be influenced by fluctuating melatonin levels.  In the MMTV/unactivated 
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Neu mouse, a diurnal rhythm of melatonin secretion exists [195].  Thus, the rise in 
melatonin during the hours of darkness and the persistence for at least eight hours may 
regulate the melatonin receptors in a way that promotes cellular differentiation through β-
arrestin scaffolds and MEK/ERK 1/2 activation [57, 59, 60].  Therefore, it was important 
to detect melatonin receptor binding sites and confirm the type of melatonin receptor in 
the mammary gland to provide support for the hypothesis of a melatonin receptor-
dependent mechanism.  To assess for melatonin specific binding sites in the mammary 
glands, radioligand binding analysis on mammary glands from Control mice was 
performed.  The mammary glands were found to express melatonin receptors at 7.8 ± 2.8 
fmol/mg protein.   
Real-time RT-PCR was performed to assess for levels of melatonin receptor 
mRNA.  The determination of melatonin receptor protein expression by western blot 
analysis or tissue distribution (i.e., epithelial or adipose) by immunohistochemisty could 
not be performed due to lack of a well-characterized and field-accepted primary 
antibodies for these receptors.  The results of the real-time RT-PCR analysis indicated 
that MT2 receptor mRNA was detected in the mammary tissue in four of the six mice 
tested; however, no MT1 receptor mRNA was detected.  The microarray analysis 
suggested the presence of Mtnr1a mRNA, but this was not confirmed by the real-time 
RT-PCR analysis.  These data indicate that the relative expression of the melatonin 
receptors was low, and, in the mammary glands, the MT2 receptor is the primary 
melatonin receptor subtype expressed.  However, the possibility of MT1 receptor 
expression was not excluded.  The results suggested that the protective actions of 
EPMRT on mammary tumorigenesis and the effects of melatonin on mammary 
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differentiation may be attributed, in part, to the actions of melatonin at MT2 receptors in 
the mammary gland.  We further suggest that the effects of melatonin are not receptor 
independent because there was no change in tumor incidence in the tumor study which 
was hypothesized to have occurred if melatonin was acting as a free radical scavenger.   
In contrast to our results, Xiang S. et al. 2012 reported that in transgenic B6SJLF2 
mice over-expressing the MT1 receptor (i.e., MT1-mOE) significant reductions in 
branching occurred at 12 weeks of age.  Also, nightly melatonin administration (25 
µg/day i.p. 1 hr before lights off) for four weeks attenuated the E2 (0.1 mg pellet) plus P4 
(10mg pellet)-induced increase in ductal branching in both B6SJLF2 and MT1-mOE 
mice by eight weeks of age.  Moreover, the elevated MT1 expression in mammary glands 
of pregnant and lactating MT1-mOE mice was associated with reduced lobuloalveolar 
development as well as reduced mammary expression of phospho-STAT5, a protein 
involved with inducing tertiary side-branching [194].  These conflicting findings could be 
explained by the time of administration of these treatments.  For example, the 
administration of these treatments at the beginning of puberty, which is a critical time for 
mammary ductal growth, delays the induction of ductal differentiation while 
administration of our treatments post-pubertal enhances the initiation of ductal 
differentiation.  Therefore, the timing of drug exposure, especially melatonin, may be an 
important factor that needs to be further scrutinized.  
 Melatonin may be enhancing mammary gland differentiation through increasing 
P4 synthesis, PRA expression, and P4-mediated pathways.  P4 has been demonstrated to 
induce tertiary side-branching through actions at PRA [136, 138-140].  Thus, it was 
hypothesized that melatonin would induce ductal differentiation by increasing PRA 
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expression in the mammary gland of mice treated with Melatonin and EPMRT.  The 
levels of Pgr(A) mRNA were significantly decreased in the mammary tissues from mice 
treated with Melatonin and EPMRT.   
  The differences between the results of the tertiary branching analysis and the 
real-time RT-PCR analysis seem to be contradictory.  The tertiary branching results 
suggest that melatonin may be promoting P4 actions in the mammary gland while the 
real-time RT-PCR results revealed a reduction in levels of Pgr(A) mRNA.  For example, 
in rat gonadotropes and mouse mammary glands, E2 through actions at ERα, 
demonstrated increased expression of PRs [196-198].  Therefore, melatonin may be 
reducing E2 actions thereby inhibiting E2-induced PRA expression as observed in the 
real-time RT-PCR results.  However, PRA expression levels in the mammary glands 
were not assessed by western blot or immunohistochemistry analyses.  Therefore, future 
studies will need to assess if the decrease in Pgr(A) mRNA relates to changes in PRA 
expression.  Also, the increase in tertiary branching may indicate that melatonin is 
stimulating tertiary branching without the need for increasing PRA expression.  As the 
process of tertiary branching may have already been completed, the mRNA results may 
not reflect the changes that occurred in the developing gland undergoing this initial stage 
of differentiation.  In conclusion, the effects through PRA are unlikely to be solely 
responsible for the melatonin-induced tertiary side-branching in the Melatonin and 
EPMRT groups.  
To further characterize the progression of mammary differentiation, 
lobuloalveolar development, an indicator of a fully differentiated mammary duct, was 
assessed.  Lobuloalveolar development is characterized by extensive expanding of the 
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mammary ducts that fills the stroma, and this event occurs during pregnancy to prepare 
the ducts for lactation.  Collectively, none of the mammary glands of any treatment 
displayed lobuloalveolar development (data not shown).  The assessment of 
lobuloalveolar development was important to further characterize the type of PR 
expressed in the mammary gland.  Pregnancy induces the expression of PRB and P4 
actions at PRB drive lobuloalveolar growth in mice.  Therefore, we conclude that P4 
signaling in virgin glands of the treated mice occurred mostly through PRA.  Overall, 
melatonin induced the initial stage of differentiation (i.e., tertiary side-branching) in the 
mammary gland, and this may have contributed to the reduced tumor formation by 
EPMRT through initiating ductal differentiation earlier in these mice.       
The hypothesis that genetic expression changes or mutations are involved in 
cancer development especially in genes that control cell growth, survival, and/or 
differentiation is generally accepted and supported.  Results from randomized clinical 
trials suggest that estrogen plus progestogen therapies increase the risk of breast cancer 
unlike estrogen alone therapies [1].  These findings suggest that the mitogenic actions of 
progestogens increase the likelihood of developing new mutations [1, 199, 200].  
However, the mitogenic actions of progestogens are controversial, and it is believed that 
the type of progestogen may be crucial to the risk of breast cancer [1].  In addition to 
progestogens, estrogen may also have a role as estrogen is required to induce 
tumorigenesis in the MMTV/unactivated mouse model.   
E2-induced mammary tumorigenesis in MMTV/unactivated Neu mice was 
independent of MMTV activity, and the tumors were characterized by having an 
increased proliferative rate, higher histologic grade, an increase in multiplicity, and a 
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shorter latency of development [147].  Higher proliferative rates were observed in 
mammary tumor-derived cell lines taken from E2 exposed mice [145, 146].  The timing 
of E2 exposure may be important because short-term E2 exposure during the early 
reproductive period promoted mammary tumorigenesis with a peak window of risk 
between 8 to 16 weeks of age [145].  Also, ovariectomies performed at six weeks of age 
in the mice resulted in a reduction of both abnormal terminal end buds and hyperplastic 
ducts as compared to intact mice suggesting that proliferation of terminal end buds and 
ducts was ovarian dependent and associated with ERα-positive cells [124].  Subsequent 
investigations with mammary tumor-derived cell lines demonstrated that E2 induces 
HRG, a ligand for the ERBB3 receptor, resulting in heterodimer formation with ERBB2.  
The dimerization activated the ERBB2 leading to the activation of MAPK and 
PI3K/AKT pathways.  This E2-induced cell proliferation was inhibited by ICI-182,780 
(Fulvestrant), an ER antagonist that down-regulates ERs; AG825, an ERBB2 tyrosine 
kinase inhibitor; and by siRNA to reduce ERBB3 expression [147].  Moreover, short-
term exposure with tamoxifen, an ER antagonist, abolished tumorigenesis in a high 
percentage of these mice [118].  
To investigate if the protective actions of EPMRT on mammary tumorigenesis 
may occur through alterations in gene expression, microarray analysis was performed to 
identify those genes uniquely modulated in the mammary gland following EPMRT 
treatment.  EPMRT resulted in differential expression of hundreds more genes compared 
to the other groups with more genes being repressed than induced (713 versus 204).  
Interestingly, Melatonin and EPRT induced 14 and 123 genes, respectively, and repressed 
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16 and 10 genes, respectively.  Therefore, melatonin in combination with E2 plus P4 
synergistically altered gene expression in the mammary gland. 
 To further identify those genes with expression uniquely altered by EPMRT, a 
Venn diagram was created.  EPMRT altered exclusively 827 genes and co-regulated 69 
and 13 genes with EPRT and Melatonin, respectively.  Before beginning the real-time 
RT-PCR analysis of candidate genes, the RNA samples were analyzed for the epithelial 
cell marker, Krt18, to ensure equal amounts of epithelial tissue amongst the groups.  
Also, it was important to ensure the sampling was obtained from an epithelial-enriched 
area as opposed to an adipose-enriched area.  Samples were also analyzed for lymph node 
contamination by assessing for Ms1a4, the gene encoding B-lymphocyte antigen CD20.  
Finally, levels of rat Erbb2 (Neu) mRNA were assessed to ensure no treatment effects on 
gene transcription.  No significant differences were detected among the groups 
suggesting the tissue samples expressed similar levels of rat Erbb2, Krt18, and Ms4a1 
mRNA among the groups.  The tissues selected for all groups contained high levels of 
epithelial mRNA.  Also, the samples contained very low levels, if any, of Ms1a4, the 
gene encoding B-lymphocyte antigen CD20, suggesting an absence of lymph node tissue.  
Therefore, this suggests that the mRNAs in the sample were not being diluted by mRNAs 
from the cells located in the lymph node.  These findings also suggest that alterations in 
transcription of the candidate genes were due to the treatments and not due to different 
amounts of epithelial tissue between groups or lymph node contamination.   
 The finding that the transcription of the rat Neu transgene was not significantly 
different among the groups, p = 0.25 was also important because altered expression of the 
transgene would suggest regulation of the MMTV promoter by the treatments thereby 
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influencing Erbb2 gene and subsequent receptor expression and possibly tumor 
development.  The MMTV promoter is active in virgin mice with activity increased by 
pregnancy.  The MMTV promoter contains the Long Terminal Repeat (LTR) that has 
hormone-responsive elements which control the transcription of genes.  Even though the 
MMTV promoter does not contain an ERE and was not modulated following E2 
exposure [201], the promoter was responsive to glucocorticoids, prolactin, androgens, 
and P4 [201-205].  Specifically, the promoter was induced by the binding of an activated 
PR to a cluster of five hormone responsive elements (HREs) [206].  In contrast to our 
study, Baturin D.A. et al. 2001 reported that constant nightly melatonin exposure (20 
mg/L) in MMTV/activated Neu mice resulted in a 2.5-fold reduction in levels of rat 
Erbb2 mRNA in mammary tumors suggesting a decrease of Erbb2 gene transcription 
[207].  Some factors that could have contributed to the lack of regulation of the transgene 
in our pre-tumor study include the fact that the mice were euthanized in estrus (i.e., state 
of high E2 and low P4 levels), and the serum levels of P4 were not increased by any of 
the treatments.  
 In the long-term tumor study, mice treated with EPMRT had improved tumor 
outcomes.  One of the goals of this study was to identify candidate genes underlying the 
protective effects of EPMRT on tumorigenesis.  Therefore, to confirm the results of the 
microarray, we performed real-time RT-PCR analysis on the selected candidate genes.  
These candidate genes were selected based on the following criteria:  hormone regulated, 
growth promoting, related to epithelial cell differentiation, or involved in tumorigenesis. 
To further explore the biological functions of these selected candidate genes, a DAVID 
analysis was performed.  The genes were grouped into seven clusters with the largest 
 104 
cluster involving mammary gland development and morphogenesis.  Also, the analysis 
revealed that some of candidate genes were involved with signaling or transcription 
regulation.  We performed an initial screening of these genes in mice given EPMRT for 
30 days compared to Control.  The results revealed significant decreases in levels of 
Areg, Ido1, and Pgr(A) mRNA, genes that are hormone-regulated, involved with growth 
promotion, or involved in tumorigenesis.  Moreover, a trend nearing significance was 
detected for Csn1s2a, (p = 0.06), a marker of mammary ductal differentiation.  These 
data suggest that expression of Csn1s2a mRNA may be increased due to increased ductal 
differentiation after EPMRT treatment.  Based on the results of the initial screening, 
which identified three candidate genes, we expanded the real-time RT-PCR analysis to 
include mammary tissue exposed to Melatonin or EPRT.   
The finding that the levels of Areg mRNA were significantly decreased by 
EPMRT, as well as by Melatonin, indicated a possible reduction of the EGFR (ERBB1) 
ligand.  The reduction of mRNA levels may be a result of the anti-estrogenic actions of 
melatonin because the Areg gene contains an ERE [166] and gene transcription was 
induced by E2 [181].  Therefore, melatonin may be reducing the binding of the E2-ERα 
complex to the ERE [79] thereby attenuating gene transcription that may lead to 
decreased amphiregulin protein production which would decrease ERBB1 receptor 
activation and decrease mammary epithelial cell proliferation.  Because amphiregulin 
does not bind and activate ERBB2, but does activate ERBB1, then transactivation of 
ERBB2 by ERBB1 or heterodimer formation between ERBB1 and ERBB2 may be 
occurring in the mammary tissue leading to mammary tumorigenesis.  Heterodimer 
formation between the transgene ERBB2 and endogenous ERBB1 is probably not 
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occurring because these heterodimers were not detected in the presence of EGF in tumor 
cell lines derived from MMTV/unactivated Neu mice [125].  Also Muller W.J. et al. 1996 
failed to detect ERBB1/ERBB2 heterodimers in tumor tissues from bigenic (i.e., 
expressing both the unactivated Neu and TGF-α transgenes) or parental mouse strains 
(MMTV/unactivated Neu and MMTV-TGF-α).  Their results suggested that ERBB2 and 
TGF-α may cooperate in tumorigenesis through ERBB1 and ERBB2 transactivation and 
not through heterodimerization.  Specifically, tumor formation in these mice was 
associated with ERBB2 tyrosine phosphorylation and c-SRC recruitment to the complex 
[208].  Because amphiregulin is a ligand for the ERBB1, we suggest that a reduction 
amphiregulin may reduce activation of the ERBB1 resulting in a decrease in the 
transactivation of ERBB2.  Therefore, a reduction in transgenic signaling through a 
reduction of amphiregulin by EPMRT would support our tumor study findings where 
EPMRT increased tumor latency beginning at 28 weeks and reduced overall tumor 
incidence.   
Even though heterodimers of ERBB1/ERBB2 have not been detected in tumor-
derived cells from MMTV/unactivated Neu mice, heterodimerization of the transgenic 
ERBB2 with ERBB3 may be occurring.  For example, analyses of tumor-derived tissues 
demonstrated an elevated expression of activated ERBB2 and ERBB3 receptors, but 
ERBB3 did not co-immunoprecipitate with ERBB2 [209] suggesting a transient 
interaction.  However, in another study, immunoprecipitation analysis revealed an 
interaction between these receptors [125].  Moreover, ERBB2/ERBB3 has a greater 
proliferative signal compared to other combinations of ERBB receptors [210].  
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 Indoleamine 2, 3-dioxygenase (IDO1) is an immunoregulatory enzyme that is 
expressed in various cells types including fibroblasts and immune cells (e.g., 
macrophages, monocytes, and dendritic cells).  IDO1 is induced by virus, 
lipopolysaccharide, cyclooxygenase 2 (COX-2) through prostaglandin E2, and interferon-
γ (i.e., a pro-inflammatory cytokine) [211, 212].  IDO1 is responsible for catalyzing the 
rate-limiting step in the degradation of tryptophan into N-formylkynurenine.  This 
enzyme-meditated tryptophan depletion resulted in the suppression of antigen-dependent 
T-cell activation, induced T-cell apoptosis, and promoted the differentiation of naïve T-
cells into regulatory T-cells [213].  Therefore, increasing the activity of this enzyme 
impairs antigen-dependent T-cell activation; this contributes to immune tolerance by 
providing the tumor cells a mechanism of escape from the immune system.   
In breast cancer, IDO1 is implicated in promoting tumor tolerance [214] and 
produces effects on the immune system [215, 216].  In patients with breast cancer, IDO1 
expression is increased in the primary tumor and serum [217].  Simultaneous gene 
expression of IDO1 and FOXP3, a marker of regulatory T-cells, is associated with 
sentinel lymph node metastases in breast cancer [218].  Also, over-expression of IDO1 is 
associated with poor prognosis in ovarian and colon cancer [212].  COX-2 activity 
modulates IDO1 expression levels.  For example, in animal models of cancer, blockade 
of COX-2 resulted in down-regulation of IDO1 at tumor sites suggesting that IDO1 was 
downstream of COX-2[219].  Interestingly, E2 induced IDO1 expression on monocyte-
derived dendritic cells (DC) obtained from multiple sclerosis patients [220].  Use of 
IDO1 inhibitors [1-methyl-DL-tryptophan (1MT) and methyl-thiohydantion-tryptophan 
(MTH-trp)] in combination with paclitaxel, brassinin (a phytoalexin), and 5-bromo-
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brassinin induced regression of mammary tumors in MMTV/unactivated Neu mice [215, 
221].   
In our study, EPMRT significantly decreased expression of Ido1 mRNA.  
Crabtree et al. 2006 reported an increase of Ido1 mRNA expression in the presence of E2 
that was suppressed by co-administration of E2 with P4 in the mammary glands of 
ovariectomized C57BL6 mice after 21 days of treatment.  They also demonstrated that 
the mRNA expression was a dose-responsive marker of P4 and was independent of 
treatment duration [222].  Our results did not demonstrate a significant decrease of 
mRNA expression with EPRT suggesting our dose of P4 was not high enough to result in 
a suppression of the mRNA.  However, the addition of melatonin to E2 plus P4 resulted 
in a significant reduction of mRNA expression.  Interestingly, melatonin alone did not 
significantly alter the mRNA expression suggesting an effect of melatonin in 
combination with E2 plus P4.  Overall, the decrease in the expression of Ido1 mRNA 
may suggest a reduction of enzyme levels that will then enable T-cell activity towards 
tumor cells.   
In summary, the influence of estrogen-containing hormone therapies on the uterus 
needs to be considered when developing novel hormone therapies due to the potential of 
estrogen-induced endometrial hyperplasia [1].  Estrogens stimulate proliferation of the 
uterine endometrium while P4 inhibits these effects.  Even though the P4 dose used in the 
tumor study was not enough to prevent an increase in uterine wet weight [15], melatonin 
was added to increase P4 actions and/or to reduce estrogen effects.  We hypothesized that 
nocturnal melatonin supplementation will reduce estrogenic actions in the uterus as well 
as increase the sensitivity of the uterus to circulating P4 thereby maximizing the 
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beneficial effects of our novel EPMRT.  The effects of melatonin may be occurring 
through melatonin receptor-dependent pathways because melatonin receptors are 
expressed in the uterus [15].  Even though we postulated that EPRT would promote 
uterine stimulation, we did not find any evidence of this following 30 days of exposure, 
which is in contrast to its long-term treatment effects observed in the tumor study.  
Moreover, the addition of melatonin to this therapy did not produce any uterine effects 
different from the Control.  Interestingly, our study revealed an increase in the number of 
days the mice were in estrus per estrous cycle and over a 30 day period suggesting an 
increase in estrogen activity; however, no difference in serum E2 levels occurred between 
groups.  Therefore, after long-term treatment, we postulate that the addition of melatonin 
to the combination of E2 and P4 may be reducing E2 actions in the uterus via increased 
PRA expression as well as by its anti-estrogenic [15] and anti-aromatase actions (See 
Appendix). 
 The novel replacement therapy containing melatonin (i.e., EPMRT) induced 
differentiation of the mammary ducts as indicated by an increase in tertiary side-
branching.  This increase in tertiary side-branching was also evident by the increased 
expression of Csn1s2a mRNA, a marker of epithelial cell differentiation.  Melatonin may 
have induced mammary ductal differentiation through actions on MEK/ERK 1/2 or by 
enhancing P4 actions in the gland.  The results of the real-time RT-PCR analysis revealed 
that EPMRT decreased the levels of mRNA of genes that are hormone-regulated and that 
are involved in growth promotion and tumorigenesis while at the same time increasing 
the expression of a gene involved in epithelial cell differentiation.  The decrease in 
transcription of growth promoting genes coupled with an induction of genes involved in 
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cell differentiation is hypothesized to contribute to the protective actions of EPMRT on 
mammary carcinogenesis.   
In these mice, we hypothesize that a potential mechanism involved in 
tumorigenesis is due to E2 signaling through the non-classical ERα signaling pathway 
resulting in the activation of SRC which then activates matrix metalloproteinases 
(MMPs).  The activation of MMPs enables cellular shedding of amphiregulin which can 
activate ERBB1 resulting in transactivation of the transgenic ERBB2 leading to the 
induction of tumorigenesis.  Additionally, through the classical pathway, E2-ERα 
complex formation may be inducing transcription of the Areg gene through binding to the 
ERE.  The subsequent enhancement of amphiregulin expression may increase ERBB1 
signaling that results in transactivation of the ERBB2 leading to tumorigenesis. 
Furthermore, we hypothesize that E2 induces immune tolerance to tumors by increasing 
IDO1 expression through induction of Ido1 gene transcription.  Melatonin, added in 
combination with E2 plus P4, is mostly likely inhibiting the effects of E2 by blocking the 
binding of the E2-ERα complex to the ERE thereby blocking the aforementioned 
pathways from being initiated.  Specifically, we suggest that melatonin in combination 
with E2 plus P4 blocks the activated E2-ERα-mediated cellular shedding of amphiregulin 
thereby inhibiting activity of amphiregulin at ERBB1; this ultimately reduces 
transactivation of ERBB2 leading to the reduction of tumorigenesis.  Furthermore, 
melatonin addition may inhibit the E2-ERα complex binding to ERE located on the Areg 
gene thereby reducing gene transcription ultimately leading to a decrease in amphiregulin 
expression and a decrease in epithelial cell proliferation.  Finally, we hypothesize that 
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melatonin may decrease the expression of Ido1 mRNA through inhibition of E2 actions 
(See Diagram 1).      
Overall, these findings provide important insight into the protective actions of 
EPMRT on Neu-induced mammary cancer.  Future studies will assess the role the 
proteins predicted to interact with amphiregulin and indoleamine 2, 3-dioxygenase may 
have in the protective actions of EPMRT.   Therefore, the results described herein may 
help to explain the protective actions of EPMRT on mammary tumorigenesis and against 
excessive uterine proliferation in order to advance the future use of EPMRT in women 
experiencing menopausal symptoms while providing protective actions on the breast and 
the uterus.     
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Diagram 2.  Proposed actions of EPMRT with regards to its protective effects on 
mammary tumorigenesis.  
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APPENDIX 
THE EFFECT OF PROGESTERONE AND MELATONIN ON OVARIAN 
AROMATASE mRNA EXPRESSION IN A MOUSE MODEL OF BREAST CANCER 
 
INTRODUCTION 
Aromatase 
 Melatonin and E2 have an inverse relationship, that is, when melatonin levels are 
low, E2 levels are high and when melatonin levels are high, E2 levels are low.  The 
mechanisms underlying this relationship may be through the inhibitory effects of 
melatonin on the aromatase enzyme.  Aromatase is a cytochrome P450 enzyme complex 
consisting of two components: the aromatase cytochrome P450 and a flavoprotein 
NADPH-cytochrome P450 reductase [223].  Aromatase is responsible for the 
biosynthesis of estrone (E1) and E2 from androstenedione and testosterone, respectively 
[224-226].  Aromatase is encoded by the CYP19A1 gene which contains at least 10 
promoters capable of being activated by different ligands in different tissues [227].  
Aromatase expression, activity and mRNA expression was higher in breast cancer tissue 
than non-malignant breast tissue [225, 226, 228].  This increase in aromatase expression 
may be through an induction of mRNA expression via its promoters.  For example, in 
MCF-7 cells as well as in adipose tissue taken from tumor-bearing breasts, aromatase 
expression was increased by cAMP acting on promoters I.3 and II.  However, in stromal 
fibroblasts of adipose tissue taken from non-tumor bearing breasts, aromatase expression 
was low; and it is thought that this reduced expression of aromatase was due to the 
inhibitory actions of glucocorticoids and interleukin 6, 11 on promoter I.4 [227, 229-
231].  In normal mammary tissue, the activities of 17β-hydroxysteroid dehydrogenase 
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type 2, that converts E2 to E1, and estrone sulfotransferase, that inactivates E2 and E1, 
were higher than aromatase [82]; this difference in expression patterns of these enzymes 
is thought to reduce the E2-stimulated actions on mammary tissue.   
Aromatase inhibitors 
One of the strategies used to treat certain types of breast cancer is to reduce local 
synthesis of E2 in the breast by use of aromatase inhibitors in pre- and postmenopausal 
women [224].  Aromatase inhibitors are classified into steroidal and non-steroidal 
inhibitors.  Steroidal inhibitors are androgen analogs that interfere with the substrate 
binding site of the enzyme while non-steroidal inhibitors inhibit the electron transfer of 
the cytochrome P450 group.  Examples of the steroidal inhibitors are testolactone (first 
generation), formestane (second generation), exemestane, and atamestane (third 
generation).  Examples of non-steroidal inhibitors are aminoglutethimide (first 
generation), fadrozole (second generation), anastrozole and letrozole (third generation) 
[225].  Aminoglutethimide is a competitive (i.e., reversible) aromatase inhibitor that 
binds to the heme moiety on aromatase thereby reducing activity without direct effect on 
mRNA expression [232].  
Melatonin has been demonstrated to inhibit mRNA expression and activity of 
aromatase.  For example, after 24 hours of incubation, melatonin at physiological (1 nM) 
and supraphysiological (10 µM) doses attenuated cAMP- and cortisol-induced aromatase 
activity [71].  Moreover, the expression of aromatase mRNA decreased following 90 
minute melatonin (1 nM) incubation [71].  Melatonin, acting through MT1 receptors 
which are Gi protein coupled receptors, decreases cAMP levels.  This reduction of cAMP 
is thought to regulate negatively promoters I.3 and II to reduce mRNA expression [155] 
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translating to tumor inhibitory actions in vivo.  The reduction in tumorigenesis by 
inhibiting aromatase with melatonin is supported, in part, by a study in female Sprague-
Dawley rats.  In this study, it was demonstrated that melatonin supplementation via 
drinking water (500 µg/day) inhibited the growth of DMBA-induced tumors in female 
Sprague-Dawley rats through an inhibition of tumor aromatase activity [233].     
The focus of this mini-study was to assess melatonin, EPRT, and EPMRT effects 
on mRNA expression of Cyp19a1 in the ovaries of MMTV/unactivated Neu mice.  The 
results of this mini-study will provide evidence that melatonin is a transcriptional 
inhibitor of aromatase and is an anti-estrogenic compound, in part, through its actions on 
expression of Cyp19a1 mRNA.   
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METHODS 
 The expression of Cyp19a1 mRNA was assessed in ovarian tissue taken from 
female mice exposed to vehicle, melatonin, and combinations of melatonin, E2, and P4 
where the dose of P4 was varied (see Table 5 for all groups) by real time RT-PCR.  It was 
hypothesized that the groups containing the lowest dose of P4 (i.e., 25 mg) would have 
the highest levels Cyp19a1 mRNA, and the addition of melatonin would block these 
increases.   
 Isoflavone-
free Diet 
(Continuous) 
Isoflavone-free Diet 
containing 
0.5 mg E2 + 25 mg P4 
(Continuous) 
Isoflavone-free Diet 
containing 
0.5 mg E2 + 50 mg P4 
(Continuous) 
Isoflavone-free Diet 
containing 
0.5 mg E2 + 100 mg P4 
(Continuous) 
Water containing 
Vehicle 
(Night Only) 
 
Control 
 
EPLRT  
 
EPMRT  
 
EPHRT  
Water containing 
Melatonin  
(Night Only) 
 
Melatonin 
 
EPLMRT  
 
EPMMRT  
 
EPHMRT  
 
Table 5.  Treatment groups 
The treatments used to study the anti-aromatase effects of melatonin in the ovary 
are described in Table 5.  At postnatal day 60 (i.e., two months of age), the mice began 
exposure to the treatment conditions.  Depending on the experimental group, nocturnal 
melatonin supplementation (final concentration of 15 mg/L) was delivered in the drinking 
water during the hours of darkness.  This supplementation was prepared daily by 
dissolving melatonin in 95% ethanol and then diluting this stock solution with water to a 
final concentration of 15 mg/L.  Mice in the melatonin group were given melatonin in the 
drinking water between the hours of 18:00 to 06:00 (i.e., 6 p.m. to 6 a.m.) each day for 30 
days.  Each mouse is estimated to consume approximately 52.5 µg of melatonin per 
period of darkness based on the measured mean nightly consumption of 3.5 mL of water.  
 116 
The melatonin dose is approximately equivalent to 5 mg of melatonin consumed by an 
adult woman per night.  Mice not consuming the nocturnal melatonin supplementation 
were provided water containing a final ethanol concentration of 0.03% (i.e., vehicle 
water). 
Depending on the experimental group, mice were provided a combination of 17β-
estradiol (E2) and progesterone (P4) in the isoflavone-free diet.  The hormones were 
blended into the diet by the supplier.  The isoflavone-free diet containing the hormones 
was provided, ad libitum, to the EPRT and EPMRT groups beginning at postnatal day 60 
and continuing until postnatal day 90, or after, until the mouse was in estrus, as 
confirmed by visualization of the vaginal smear.  The dose of E2 (0.5 mg)  or P4 925 mg, 
50 mg, or 100 mg) was added to 1800 kcal of diet, the average daily caloric intake of a 
woman [128], to account for the metabolic differences between mice and humans.  
Therefore, the final daily hormonal doses consumed by the mice eating 18 kcal of diet 
would be 5 µg of E2 and 250 µg, 500 µg and 1000 µg of P4.  Following completion of 
the experimental time-line, the mice were euthanized by carbon dioxide inhalation.  
Ovaries were collected, frozen immediately in liquid nitrogen, and stored at -80
o
C.     
Real-time RT-PCR  
 As conducted by Dr. Emilio Jose Sanchez-Barcelo’s laboratory 
Following the manufacturer’s instructions, total cellular RNA from the ovaries 
was purified with TRI-Reagent (Sigma).  Purity was determined by calculating the 
absorbance ratio (i.e., 260/280 nm), and all preparation were greater than 1.9.  Gel 
electrophoresis, using ethidium bromide-stained 1.2% agarose-Tris-borate EDTA gels, 
was performed to determine RNA integrity.  RNA was denatured at 65º C for ten minutes 
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prior to being reverse transcribed using the cDNA Synthesis Kit (Bioline, London, UK)  
in the presence of 500ng of oligo(dT) 12-18 primer for 50 minutes at 45º C (total volume 
of 20μL).  Next, QPCR was conducted (in triplicate) in three independent experiments to 
ensure reproducibility using Brilliant SYBR
®
Green PCR Master Mix (Stratagene) in an 
Mx3005p (Stratagene) (final volume of 25µL).  Cycling parameters were 10 minutes at 
95º C followed by 45 seconds at 95º C (denaturing step), then one minute at 57º C 
(annealing step) and finally 45 seconds at 72º C (extension step).    
When designing the primers, the coding sequence between the two PCR primer 
sites was interrupted by at least one intron.  This was done to ensure that the 
amplification was from cDNA and not genomic DNA.  All primers were purchased from 
Sigma Genosys Ltd., (Cambridge, UK).  Primer sequence for Cyp19a1 (aromatase) F: 5’- 
GAAGTGCCTGCAACTACTAC - 3’ and R: 5’- GCATGCCGATGCACTGCAGC - 3’.  
Ribosomal subunit 14s was used as a reference gene in order to normalize RNA 
expression variation.  Primer sequence for Rps14 (ribosomal protein S14) F: 5’ – 
TCACTGCCCTGCACATCAAAC – 3’ and R: 5’- TTTCTTCGAGTGCTATCAGAG – 
3’.  Single product amplifications were verified by performing melt curves by using 
dissociation curves.     
Transcription efficiencies between the primers resulted in no significant 
differences.  The change in threshold cycle (ΔCt) was calculated for each sample, and 
aromatase gene expression for each sample was normalized to the relative expression of 
Rps14.  The fold change of expression was determined by the 2
-ΔΔCt 
method [132].     
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RESULTS 
Low dose P4 increased expression of Cyp19a1 mRNA that was abolished by increasing 
doses of P4 and by addition of melatonin 
 Aromatase is an enzyme that converts androgens to estrogens, specifically 
testosterone to E2 and androstenedione to E1.  An increase in mRNA expression may 
suggest an increase in the conversion of androgens to estrogens, thereby influencing the 
hormone environment of the mice.  To determine whether or not the treatments, 
especially those containing P4 and melatonin, altered the expression of Cyp19a1 mRNA, 
real-time RT-PCR analysis was performed on ovarian tissue.  To investigate the effects of 
P4, we assessed the expression of Cyp19a1 mRNA using low (25 mg), mid (50 mg), and 
high (100 mg) doses of P4 (each in 1800 kcal diet).  Figure 20 displays a dose-dependent 
inhibition of Cyp19a1expression by P4 whereby the lowest dose of P4 (i.e., 25 mg) 
exhibited the highest expression of Cyp19a1 mRNA, and this effect was attenuated by 
higher doses of P4 (i.e., 50 and 100 mg).  The addition of melatonin to the E2 plus P4 
containing the low dose P4 (25 mg) abolished the 25 mg P4-induced increase in 
expression of Cyp19a1 mRNA.  These data support a role for melatonin as an inhibitor of 
ovarian aromatase mRNA expression perhaps leading to a subsequent decrease in the 
synthesis of ovarian estrogens.      
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Figure 20.  Dose-dependent effects of P4 on expression of Cyp19a1 mRNA in the ovary.  
(A) A dose-dependent inhibition of Cyp19a1expression occurred with increasing doses of 
P4 compared to Control.  (B) The addition of melatonin to the low dose P4 abolished the 
increase in mRNA expression.  Each bar represents the mean ∆Ct ± SEM values from n = 
3-4 mice per treatment group.  Value inside the bar represents fold change of expression 
as determined by the 2
-ΔΔCt 
method.  Data were analyzed by one-way ANOVA followed 
by Newman-Keuls post-hoc test where significance was defined as p < 0.05 with          
(*) = p < 0.05 as compared to Control.  Lower mean ∆Ct indicates higher expression.   
 
Abbreviations:  
Con = Control; mice exposed to isoflavone-free diet and vehicle water 
EPLRT = mice exposed to 0.5mg E2 + 25mg P4 and vehicle water 
EPMRT = mice exposed to 0.5mg E2 + 50mg P4 and vehicle water 
EPHRT = mice exposed to 0.5mg E2 + 100mg P4 and vehicle water 
Mel = Melatonin; mice exposed to melatonin water during the hours of darkness 
EPLMRT = mice exposed to 0.5mg E2 + 25mg P4 and melatonin water during the hours of darkness 
EPMMRT = mice exposed to 0.5mg E2 + 50mg P4 and melatonin water during the hours of darkness 
EPHMRT = mice exposed to 0.5mg E2 + 100mg P4 and melatonin water during the hours of darkness 
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DISCUSSION 
Aromatase is responsible for the biosynthesis of E1 and E2 from androstenedione 
and testosterone, respectively [224-226].  Aromatase expression, activity and mRNA 
expression was higher in breast cancer tissue than non-malignant breast tissue [225, 226, 
228].  In normal mammary tissue, the activities of the enzymes 17β-hydroxysteroid 
dehydrogenase type 2 and estrone sulfotransferase that convert E2 to E1 and inactivates 
E2 and E1, respectively, were higher than aromatase [82].  In this study, melatonin, 
added in combination with E2 and 25mg P4, attenuated the induction of Cyp19a1 
expression by E2 and 25 mg of P4.  Melatonin has been shown in numerous studies to 
decrease the mRNA expression and activity of aromatase [71, 84, 232, 234].  Like 
melatonin, P4 is also known to inhibit aromatase mRNA expression.  For example, in 
human-derived adipose fibroblasts, P4 (10 nM-10 µM) inhibits glucocorticoid-dependent 
aromatase induction via competition for the glucocorticoid receptor and not the 
progesterone receptor [235]; thus, the dose-dependent inhibition of expression of 
Cyp19a1 mRNA by P4 may be occurring through this process in ovaries of 
MMTV/unactivated Neu mice.  Because melatonin inhibits dexamethasone-induced 
increases in mRNA expression through promoter I.4 [227, 230, 231, 236], modulation of 
the promoter by melatonin to reduce gene transcription may be another possibility.  
Melatonin can modulate the promoters through cAMP-dependent mechanisms.  
Melatonin, acting through MT1 melatonin receptors, inhibited adenylyl cyclase activity 
following activation of Gi protein.  The resulting reduction of cAMP by melatonin may 
regulate negatively promoters I.3 and II to reduce aromatase expression because cAMP is 
an inducer of aromatase expression through promoters I.3 and II [227, 229-231] with 
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melatonin being more potent at reducing promoter II activity [155].  Another way may be 
through actions of melatonin on P4 synthesis and release from the ovarian granulosa cells 
[103-107].  The increase in P4 induced by melatonin can inhibit the transcription of the 
aromatase gene through competition with glucocorticoids for binding to the 
glucocorticoid receptors [237].  Overall, our results suggest that melatonin in 
combination with E2 and P4 may attenuate both mammary epithelial cell and endometrial 
epithelial and stromal cell proliferation through anti-aromatase actions; reductions in 
estrogen and estrogen-mediated actions by melatonin may underlie the protective actions 
on the mammary gland and uterus.    
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